



National Comprehensive
Cancer Network®


NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Multiple Myeloma

NCCN Evidence Blocks™

Version 3.2019 — June 19, 2019

[NCCN.org](https://www.nccn.org)



[Continue](#)



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 3.2019

Multiple Myeloma

NCCN Evidence Blocks™

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

***Shaji K. Kumar, MD/Chair ‡ §**
Mayo Clinic Cancer Center

***Natalie S. Callander, MD/Vice Chair ‡**
University of Wisconsin
Carbone Cancer Center

J. Sybil Biermann, MD ¶
University of Michigan
Rogel Cancer Center

Jorge J. Castillo, MD ‡
Dana-Farber/Brigham and Women's
Cancer Center | Massachusetts General
Hospital Cancer Center

Jason C. Chandler, MD †
St. Jude Children's Research Hospital/
The University of Tennessee
Health Science Center

Robert F. Cornell, MD ‡ P
Vanderbilt-Ingram Cancer Center

Caitlin Costello, MD † ‡ §
UC San Diego Moores Cancer Center

Yvonne Efebera, MD, MPH ‡
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Matthew Faiman, MD P
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center
and Cleveland Clinic Taussig Cancer Institute

Kelly Godby, MD †
University of Alabama at Birmingham
Comprehensive Cancer Center

Jens Hillengass, MD ‡
Roswell Park Comprehensive Cancer Center

Leona Holmberg, MD, PhD § ‡
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Sarah Holstein, MD, PhD † ‡
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center

Myo Htut, MD ‡
City of Hope Comprehensive Cancer Center

Carol Ann Huff, MD † ‡
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Yubin Kang, MD ‡ †
Duke Cancer Institute

Ola Landgren, MD †
Memorial Sloan Kettering Cancer Center

Michaela Liedtke, MD ‡
Stanford Cancer Institute

Ehsan Malek, MD
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer
Center and Cleveland Clinic Taussig
Cancer Institute

Thomas Martin, MD
UCSF Helen Diller Family
Comprehensive Cancer Center

James Omel, MD
Patient Advocate

Noopur Raje, MD † ‡
Dana-Farber/Brigham and Women's Cancer
Center | Massachusetts General Hospital
Cancer Center

Seema Singhal, MD ‡
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Keith Stockerl-Goldstein, MD † §
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Carlyn Tan, MD
Fox Chase Cancer Center

Donna Weber, MD † ‡ P
The University of Texas
MD Anderson Cancer Center

NCCN
Alyse Johnson-Chilla, MS
Rashmi Kumar, PhD

[NCCN Guidelines Panel Disclosures](#)

Continue

† Medical oncology	§ Radiotherapy/Radiation oncology
‡ Hematology	P Internal medicine
§ Bone marrow transplantation	* Discussion section writing committee
¶ Surgery/Surgical oncology	



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 3.2019

Multiple Myeloma

NCCN Evidence Blocks™

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

[NCCN Multiple Myeloma Panel Members](#) [Evidence Blocks Definitions \(EB-1\)](#)

[Initial Diagnostic Workup and Clinical Presentation \(MYEL-1\)](#)

[Solitary Plasmacytoma \(Osseous or Extraosseous\) Primary Treatment \(MYEL-2\)](#)

[Smoldering \(Asymptomatic\) Myeloma: Primary Treatment and Follow-Up/Surveillance \(MYEL-3\)](#)

[Active \(Symptomatic\) Myeloma: Primary Treatment and Follow-Up/Surveillance \(MYEL-4\)](#)

[Active \(Symptomatic\) Myeloma: Response after Primary Treatment and Follow-Up/Surveillance \(MYEL-5\)](#)

[Additional Treatment Post Stem Cell Transplant \(MYEL-6\)](#)

[Active Disease: Additional Treatment for Relapse or Progressive Disease \(MYEL-7\)](#)

[Staging Systems for Multiple Myeloma \(MYEL-A\)](#)

[Definition of Multiple Myeloma \(Smoldering and Active\) \(MYEL-B\)](#)

[Principles of Radiation Therapy \(MYEL-C\)](#)

[Response Criteria for Multiple Myeloma \(MYEL-D\)](#)

[Myeloma Therapy \(MYEL-E\)](#)

[Supportive Care Treatment for Multiple Myeloma \(MYEL-F\)](#)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here:
nccn.org/clinical_trials/clinicians.aspx](#).

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

NCCN Categories of Preference: All recommendations are considered appropriate.

See [NCCN Categories of Preference](#)

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Evidence Blocks™ and NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Evidence Blocks™, NCCN Guidelines, and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2019.



NCCN Guidelines Version 3.2019

Multiple Myeloma

NCCN Evidence Blocks™

NCCN EVIDENCE BLOCKS CATEGORIES AND DEFINITIONS

5					
4					
3					
2					
1					

E S Q C A

E = Efficacy of Regimen/Agent
 S = Safety of Regimen/Agent
 Q = Quality of Evidence
 C = Consistency of Evidence
 A = Affordability of Regimen/Agent

Example Evidence Block

5					
4					
3					
2					
1					

E S Q C A

Efficacy of Regimen/Agent

5	Highly effective: Cure likely and often provides long-term survival advantage
4	Very effective: Cure unlikely but sometimes provides long-term survival advantage
3	Moderately effective: Modest impact on survival, but often provides control of disease
2	Minimally effective: No, or unknown impact on survival, but sometimes provides control of disease
1	Palliative: Provides symptomatic benefit only

Safety of Regimen/Agent

5	Usually no meaningful toxicity: Uncommon or minimal toxicities; no interference with activities of daily living (ADLs)
4	Occasionally toxic: Rare significant toxicities or low-grade toxicities only; little interference with ADLs
3	Mildly toxic: Mild toxicity that interferes with ADLs
2	Moderately toxic: Significant toxicities often occur but life threatening/fatal toxicity is uncommon; interference with ADLs is frequent
1	Highly toxic: Significant toxicities or life threatening/fatal toxicity occurs often; interference with ADLs is usual and severe

Note: For significant chronic or long-term toxicities, score decreased by 1

Quality of Evidence

5	High quality: Multiple well-designed randomized trials and/or meta-analyses
4	Good quality: One or more well-designed randomized trials
3	Average quality: Low quality randomized trial(s) or well-designed non-randomized trial(s)
2	Low quality: Case reports or extensive clinical experience
1	Poor quality: Little or no evidence

Consistency of Evidence

5	Highly consistent: Multiple trials with similar outcomes
4	Mainly consistent: Multiple trials with some variability in outcome
3	May be consistent: Few trials or only trials with few patients, whether randomized or not, with some variability in outcome
2	Inconsistent: Meaningful differences in direction of outcome between quality trials
1	Anecdotal evidence only: Evidence in humans based upon anecdotal experience

Affordability of Regimen/Agent (includes drug cost, supportive care, infusions, toxicity monitoring, management of toxicity)

5	Very inexpensive
4	Inexpensive
3	Moderately expensive
2	Expensive
1	Very expensive

**INITIAL DIAGNOSTIC WORKUP**

- History and physical exam
- CBC, differential, platelet count
- Exam of peripheral blood smear
- Serum BUN/creatinine, electrolytes, albumin,^a and calcium
- Creatinine clearance (calculated or measured directly)
- Serum uric acid
- Serum LDH^a and beta-2 microglobulin^a
- Serum quantitative immunoglobulins, serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (SIFE)
- 24-h urine for total protein, urine protein electrophoresis (UPEP), urine immunofixation electrophoresis (UIFE)
- Serum free light chain (FLC) assay
- Skeletal survey or whole body low-dose CT scan^{b,c}
- Unilateral bone marrow aspirate + biopsy, including bone marrow immunohistochemistry and/or bone marrow flow cytometry
- Metaphase cytogenetics on bone marrow
- Plasma cell FISH^a [del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification], 1p abnormality

Useful In Certain Circumstances

- Whole body or skeletal MRI or whole body FDG PET/CT scan^{b,c}
 - Tissue biopsy to diagnose a solitary osseous or extraosseous plasmacytoma
 - Plasma cell proliferation
 - Serum viscosity
 - HLA typing
 - Echocardiogram
 - Evaluate for light chain amyloidosis, if appropriate
- [See NCCN Guidelines for Systemic Light Chain Amyloidosis](#)

CLINICAL PRESENTATIONSolitary plasmacytoma^d[See Solitary Osseous: Primary Treatment \(MYEL-2\)](#)[See Solitary Extraosseous: Primary Treatment \(MYEL-2\)](#)Smoldering (asymptomatic)^{d,e}[See Primary Treatment \(MYEL-3\)](#)Active (symptomatic)^{d,e}[See Primary Treatment \(MYEL-4\)](#)^a These tests are essential for R-ISS staging.^b Additional testing (whole body or skeletal MRI or whole body FDG PET/CT scan) is recommended to discern active from smoldering myeloma, if skeletal survey is negative. If FDG PET/CT has been done, then skeletal survey is not needed.^c Consider using the same imaging modality used during the initial workup for the follow-up assessments.^d [See Staging Systems for Multiple Myeloma \(MYEL-A\).](#)^e [See Definition of Multiple Myeloma \(Smoldering and Active\) \(MYEL-B\).](#)**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page EB-1.****All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



NCCN Guidelines Version 3.2019


Multiple Myeloma

NCCN Evidence Blocks™

CLINICAL PRESENTATION

PRIMARY TREATMENT

FOLLOW-UP/SURVEILLANCE^c



^c Consider using the same imaging modality used during the initial workup for the follow-up assessments.

^f Consider surgery if structurally unstable or if there is neurologic compromise due to mass effect.

^g [See Principles of Radiation Therapy \(MYEL-C\).](#)

^h Patients with soft tissue and head/neck plasmacytoma could be followed less frequently after initial 3-month follow-up.

ⁱ [See Response Criteria for Multiple Myeloma \(MYEL-D\).](#)

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 3.2019

Multiple Myeloma

NCCN Evidence Blocks™

**CLINICAL
PRESENTATION****PRIMARY
TREATMENT****FOLLOW-UP/SURVEILLANCE^c**Smoldering
(asymptomatic)^{d,e,j}Observe at 3-
to 6-mo
intervals
(category 1)
or
Clinical trial

- CBC, differential, platelet count
- Creatinine, corrected calcium
- Serum quantitative immunoglobulins, SPEP, SIFE
- 24-h urine for total protein, UPEP, UIFE
- Serum FLC assay as clinically indicated
- Skeletal survey or whole body low-dose CT scan as clinically indicated
- Bone marrow aspirate and biopsy with FISH and multi-parameter flow cytometry as clinically indicated
- Whole body or skeletal MRI or whole body FDG PET/CT scan as clinically indicated

Progression to
symptomatic
myeloma[See Active
\(symptomatic\)
\(MYEL-4\)](#)^c Consider using the same imaging modality used during the initial workup for the follow-up assessments.^d [See Staging Systems for Multiple Myeloma \(MYEL-A\).](#)^e [See Definition of Multiple Myeloma \(Smoldering and Active\) \(MYEL-B\).](#)^j A relatively small randomized prospective study has shown benefit of early treatment with lenalidomide and dexamethasone for a subset of patients with smoldering myeloma with certain high-risk features predictive for early clinical progression (Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smoldering multiple myeloma (QuiRedex): long-term follow-up of a randomized, controlled, phase 3 trial. *Lancet Oncol* 2016;17(8):1127-1136). However, the high-risk criteria specified in the study are not in common use. Alternative criteria have been described (Dispenzieri A, Kyle R, Katzmann J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. *Blood* 2008;111(2):785-789). The NCCN Panel strongly recommends enrolling eligible smoldering myeloma patients with high-risk criteria in clinical trials.**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).****All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 3.2019

Multiple Myeloma


NCCN Evidence Blocks™

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

CLINICAL PRESENTATION

PRIMARY TREATMENT

FOLLOW-UP/SURVEILLANCE^c



^c Consider using the same imaging modality used during the initial workup for the follow-up assessments.

^d [See Staging Systems for Multiple Myeloma \(MYEL-A\).](#)

^e [See Definition of Multiple Myeloma \(Smoldering and Active\) \(MYEL-B\).](#)

ⁱ [See Response Criteria for Multiple Myeloma \(MYEL-D\).](#)

^k [See Myeloma Therapy \(MYEL-E\).](#)

^l [See Supportive Care Treatment for Multiple Myeloma M \(MYEL-F\).](#)

^m Autologous transplantation: Category 1 evidence supports proceeding directly after induction therapy to high-dose therapy and stem cell transplant versus saving the stem cell transplant for salvage therapy. Evidence suggests equivalent overall survival, although progression-free survival can be prolonged by an early transplant. [\(See Discussion\).](#)

ⁿ Renal dysfunction and advanced age are not contraindications to transplant.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).


All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



ACTIVE (SYMPTOMATIC) MYELOMA

FOLLOW-UP/SURVEILLANCE^c



^c Consider using the same imaging modality used during the initial workup for the follow-up assessments.

ⁱ [See Response Criteria for Multiple Myeloma \(MYEL-D\)](#).

^k [See Myeloma Therapy \(MYEL-E\)](#).

^m Autologous transplantation: Category 1 evidence supports proceeding directly after induction therapy to high-dose therapy and stem cell transplant versus saving the stem cell transplant for salvage therapy. Evidence suggests equivalent overall survival, although progression-free survival can be prolonged by an early transplant. ([See Discussion](#)).

ⁿ Renal dysfunction and advanced age are not contraindications to transplant.

^o Allogeneic stem cell transplant may include nonmyeloablative (mini) following autologous stem cell transplant or fully myeloablative, preferably in a clinical trial. Current data do not support miniallografting alone.

^p A majority of phase 3 trials do not show a survival advantage for allogeneic SCT compared with autologous SCT. ([See Discussion](#)).

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



ACTIVE (SYMPTOMATIC) MYELOMA

ADDITIONAL TREATMENT

Post-allogeneic stem cell transplant:



Post-autologous stem cell transplant (single or tandem):



ⁱ See Response Criteria of Multiple Myeloma (MYEL-D).

^k See Myeloma Therapy (MYEL-E).

^o Allogeneic stem cell transplant may include nonmyeloablative (mini) following autologous stem cell transplant or fully myeloablative, preferably in a clinical trial. Current data do not support miniallografting alone.

^q Additional autologous transplant on or off clinical trial is an option depending on the time interval between the preceding stem cell transplant and documented progression. Retrospective studies suggest a 2- to 3-year minimum length of remission for consideration of a second autologous stem cell transplant.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).


All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



ACTIVE (SYMPTOMATIC) MYELOMA

ADDITIONAL TREATMENT (FOR PATIENTS TREATED WITH OR WITHOUT A PRIOR TRANSPLANT)



ⁱ [See Response Criteria for Multiple Myeloma \(MYEL-D\).](#)

^k [See Myeloma Therapy \(MYEL-E\).](#)

^m Autologous transplantation: Category 1 evidence supports proceeding directly after induction therapy to high-dose therapy and stem cell transplant versus saving the stem cell transplant for salvage therapy. Evidence suggests equivalent overall survival, although progression-free survival can be prolonged by an early transplant. [\(See Discussion\).](#)

^o Allogeneic stem cell transplant may include nonmyeloablative (mini) following autologous stem cell transplant or fully myeloablative, preferably in a clinical trial. Current data do not support miniallografting alone.

^r Assess for stem cell transplant candidacy.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



STAGING SYSTEMS FOR MULTIPLE MYELOMA¹

Stage	International Staging System (ISS)	Revised-ISS (R-ISS)
I	Serum beta-2 microglobulin <3.5 mg/L, Serum albumin ≥3.5 g/dL	ISS stage I and standard-risk chromosomal abnormalities by FISH ² and Serum LDH ≤ the upper limit of normal
II	Not ISS stage I or III	Not R-ISS stage I or III
III	Serum beta-2 microglobulin ≥5.5 mg/L	ISS stage III and either high-risk chromosomal abnormalities by FISH ² or Serum LDH > the upper limit of normal

¹ Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group. J Clin Oncol 2015;33:2863-2869.

² Standard-risk: No high-risk chromosomal abnormality. High-risk: Presence of del(17p) and/or translocation t(4;14) and/or translocation t(14;16).

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



DEFINITION OF MULTIPLE MYELOMA (SMOLDERING AND ACTIVE)

Smoldering (Asymptomatic) Myeloma^{1,2}

- Serum monoclonal protein ≥ 3 g/dL
- Or*
- Bence-Jones protein ≥ 500 mg/24 h
- And/Or*
- Clonal bone marrow plasma cells 10%–59%
- And*
- Absence of myeloma-defining events or amyloidosis
 - ▶ If skeletal survey negative, assess for bone disease with whole body MRI, FDG PET/CT, or low-dose CT scan.

Active (Symptomatic) Myeloma^{2,3}

- Clonal bone marrow plasma cells $\geq 10\%$ or biopsy-proven bony or extramedullary plasmacytoma
- And*
- Any one or more of the following myeloma-defining events:
- Calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or >2.75 mmol/L (>11 mg/dL)
 - Renal insufficiency (creatinine >2 mg/dL) [>177 $\mu\text{mol/L}$] or creatinine clearance <40 mL/min
 - Anemia (hemoglobin <10 g/dL or hemoglobin >2 g/dL below the lower limit of normal)
 - One or more osteolytic bone lesions on skeletal radiography, CT, or FDG PET/CT
 - Clonal bone marrow plasma cells $\geq 60\%$
 - Abnormal serum FLC ratio ≥ 100 (involved kappa) or ≤ 0.01 (involved lambda)
 - >1 focal lesions on MRI studies ≥ 5 mm

¹ The understanding of smoldering (asymptomatic) myeloma is evolving rapidly. Some studies have shown that patients with certain characteristics, including IgG levels of >3 g/dL, IgA of >2 g/dL, or urinary Bence Jones protein of >1 g/24 h (Mateos MV, Hernandez M, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:438-447) or abnormal free light chain ratios (Dispienzeri A, Kyle R, Katzmman J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785-789) have an increased risk of progression to active (symptomatic) myeloma. It is also increasingly recognized that the classical definition of smoldering myeloma using certain tests such as plain x-rays is outdated. Efforts to modify these criteria and reclassify some patients previously classified as “asymptomatic” to having “active disease” are underway.

² Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;Vol 15,e538-e548.

³ Other examples of active disease include: repeated infections, amyloidosis, light chain deposition disease, or hyperviscosity.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF RADIATION THERAPY

General Treatment Information/Dosing

- Solitary osseous ([MYEL-2](#))
 - ▶ RT (40–50 Gy in 1.8–2.0 Gy/fraction) to involved field
- Solitary extraosseous ([MYEL-2](#))
 - ▶ RT (40–50 Gy in 1.8–2.0 Gy/fraction) to involved field
- Palliative ([MYEL-F](#))
 - ▶ Low-dose RT (8 Gy x 1 fraction or 10–30 Gy in 2.0–3.0 Gy fractions) can be used as palliative treatment for uncontrolled pain, for impending pathologic fracture, or for impending cord compression.
 - ▶ Limited involved fields should be used to limit the impact of irradiation on stem-cell harvest or impact on potential future treatments.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 3.2019

Multiple Myeloma

NCCN Evidence Blocks™

RESPONSE CRITERIA FOR MULTIPLE MYELOMA (Revised based on the new criteria by International Myeloma Working Group [IMWG])

IMWG criteria for response assessment including criteria for minimal residual disease (MRD)	
Response Category ^a	Response Criteria
IMWG MRD criteria (requires a complete response as defined below)	
Sustained MRD-negative	MRD negativity in the marrow (next-generation flow [NGF], next-generation sequencing [NGS], or both) and by imaging as defined below, confirmed minimum of 1 year apart. Subsequent evaluations can be used to further specify the duration of negativity (eg, MRD-negative at 5 years). ^b
Flow MRD-negative	Absence of phenotypically aberrant clonal plasma cells by NGF ^c on bone marrow aspirates using the EuroFlow standard operation procedure for MRD detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 10 ⁵ nucleated cells or higher.
Sequencing MRD-negative	Absence of clonal plasma cells by NGS on bone marrow aspirate in which presence of a clone is defined as less than two identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using a validated equivalent method with a minimum sensitivity of 1 in 10 ⁵ nucleated cells ^d or higher.
Imaging plus MRD-negative	MRD negativity as defined by NGF or NGS plus disappearance of every area of increased tracer uptake found at baseline or a preceding FDG PET/CT or decrease to less mediastinal blood pool standardized uptake value (SUV) or decrease to less than that of surrounding normal tissue. ^e
Standard IMWG response criteria ^f	
Stringent complete response	Complete response as defined below plus normal FLC ratio ^g and absence of clonal cells in bone marrow biopsy by immunohistochemistry (κ/λ ratio ≤4:1 or ≥1:2 for κ and λ patients, respectively, after counting ≥100 plasma cells). ^h
Complete response ⁱ	Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow aspirates.
Very good partial response	Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 h.
Partial response	≥50% reduction of serum M-protein plus reduction in 24-h urinary M-protein by ≥90% or to <200 mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum-free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma-cell percentage was ≥30%. In addition to these criteria, if present at baseline, a ≥50% reduction in the size (sum of the products of the maximal perpendicular diameters [SPD] of measured lesions) ^j of soft tissue plasmacytomas is also required.
Minimal response	≥25% but ≤49% reduction of serum M-protein and reduction in 24-h urine M-protein by 50%–89%. In addition to the above listed criteria, if present at baseline, a 25%–49% reduction in SPD ^j of soft tissue plasmacytomas is also required.

Reprinted from The Lancet Oncology, 17: Kumar S, Paiva B, Anderson K, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, e328–46, Copyright (2016), with permission from Elsevier.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)
[Footnotes](#)

MYEL-D
1 OF 3



NCCN Guidelines Version 3.2019

Multiple Myeloma

NCCN Evidence Blocks™

RESPONSE CRITERIA FOR MULTIPLE MYELOMA (Revised based on the new criteria by International Myeloma Working Group [IMWG])	
Response Category ^a	Response Criteria
Stable disease	Not recommended for use as an indicator of response; stability of disease is best described by providing the time-to-progression estimates. Not meeting criteria for complete response, very good partial response, partial response, minimal response, or progressive disease.
Progressive disease ^{k,l}	Any one or more of the following criteria: Increase of 25% from lowest confirmed response value in one or more of the following criteria: Serum M-protein (absolute increase must be ≥ 0.5 g/dL); Serum M-protein increase ≥ 1 g/dL, if the lowest M component was ≥ 5 g/dL; Urine M-protein (absolute increase must be ≥ 200 mg/24 h); In patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels (absolute increase must be >10 mg/dL); In patients without measurable serum and urine M-protein levels and without measurable involved FLC levels, bone marrow plasma-cell percentage irrespective of baseline status (absolute increase must be $\geq 10\%$); Appearance of a new lesion(s), $\geq 50\%$ increase from nadir in SPD ^j of >1 lesion, or $\geq 50\%$ increase in the longest diameter of a previous lesion >1 cm in short axis; $\geq 50\%$ increase in circulating plasma cells (minimum of 200 cells per μ L) if this is the only measure of disease.
Clinical relapse	Clinical relapse requires one or more of the following criteria: Direct indicators of increasing disease and/or end organ dysfunction (calcium elevation, renal failure, anemia, lytic bone lesions [CRAB features]) related to the underlying clonal plasma cell proliferative disorder. It is not used in calculation of time to progression or progression-free survival but is listed as something that can be reported optionally or for use in clinical practice; Development of new soft tissue plasmacytomas or bone lesions (osteoporotic fractures do not constitute progression); Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and ≥ 1 cm) increase as measured serially by the SPD ^j of the measurable lesion; Hypercalcemia (>11 mg/dL); Decrease in hemoglobin of ≥ 2 g/dL not related to therapy or other non–myeloma-related conditions; Rise in serum creatinine by 2 mg/dL or more from the start of the therapy and attributable to myeloma; Hyperviscosity related to serum paraprotein.
Relapse from complete response (to be used only if the endpoint is disease-free survival)	Any one or more of the following criteria: Reappearance of serum or urine M-protein by immunofixation or electrophoresis ⁱ ; Development of $\geq 5\%$ plasma cells in the bone marrow; Appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcemia) (see above).
Relapse from MRD negative (to be used only if the endpoint is disease-free survival)	Any one or more of the following criteria: Loss of MRD negative state (evidence of clonal plasma cells on NGF or NGS, or positive imaging study for recurrence of myeloma); Reappearance of serum or urine M-protein by immunofixation or electrophoresis; Development of $\geq 5\%$ clonal plasma cells in the bone marrow; Appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcemia).

Reprinted from The Lancet Oncology, 17: Kumar S, Paiva B, Anderson K, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, e328–46, Copyright (2016), with permission from Elsevier.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Footnotes

**RESPONSE CRITERIA FOR MULTIPLE MYELOMA****Footnotes**

^aAll response categories require two consecutive assessments made any time before starting any new therapy; for MRD there is no need for two consecutive assessments, but information on MRD after each treatment stage is recommended (eg, after induction, high-dose therapy/ASCT, consolidation, maintenance). MRD tests should be initiated only at the time of suspected complete response. All categories of response and MRD require no known evidence of progressive or new bone lesions if radiographic studies were performed. However, radiographic studies are not required to satisfy these response requirements except for the requirement of FDG PET if imaging MRD-negative status is reported.

^bSustained MRD negativity when reported should also annotate the method used (eg, sustained flow MRD-negative, sustained sequencing MRD-negative).

^cBone marrow MFC should follow NGF guidelines. The reference NGF method is an eight-color two-tube approach, which has been extensively validated. The two-tube approach improves reliability, consistency, and sensitivity because of the acquisition of a greater number of cells. The eight-color technology is widely available globally and the NGF method has already been adopted in many flow laboratories worldwide. The complete eight-color method is most efficient using a lyophilised mixture of antibodies, which reduces errors, time, and costs. Five million cells should be assessed. The FCM method employed should have a sensitivity of detection of at least 1 in 10⁵ plasma cells. Paiva B, Gutierrez NC, Rosinol L, et al, for the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. *Blood* 2012; 119: 687–91.

^dDNA sequencing assay on bone marrow aspirate should use a validated assay.

^eCriteria used by Zamagni and colleagues, and expert panel (IMPetUs; Italian Myeloma Criteria for PET Use). Baseline positive lesions were identified by presence of focal areas of increased uptake within bones, with or without any underlying lesion identified by CT and present on at least two consecutive slices. Alternatively, an SUVmax = 2.5 within osteolytic CT areas >1 cm in size, or SUVmax = 1.5 within osteolytic CT areas ≤1 cm in size were considered positive. Imaging should be performed once MRD negativity is determined by MFC or NGS. Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. *Clin Cancer Res* 2015; 21: 4384–90.

^fDerived from international uniform response criteria for multiple myeloma. Minor response definition and clarifications derived from Rajkumar and colleagues. When the only method to measure disease is by serum FLC levels: complete response can be defined as a normal FLC ratio of 0.26 to 1.65 in addition to

Reprinted from *The Lancet Oncology*, 17: Kumar S, Paiva B, Anderson K, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, e328–46, Copyright (2016), with permission from Elsevier.

the complete response criteria listed previously. Very good partial response in such patients requires a ≥90% decrease in the difference between involved and uninvolved FLC levels. All response categories require two consecutive assessments made at any time before the institution of any new therapy; all categories also require no known evidence of progressive or new bone lesions or extramedullary plasmacytomas if radiographic studies were performed. Radiographic studies are not required to satisfy these response requirements. Bone marrow assessments do not need to be confirmed. Each category, except for stable disease, will be considered unconfirmed until the confirmatory test is performed. The date of the initial test is considered as the date of response for evaluation of time dependent outcomes such as duration of response. Durie BG, Harousseau JL, Miguel JS, et al, for the International Myeloma Working Group. International uniform response criteria for multiple myeloma. *Leukemia* 2006; 20: 1467–73.

^gAll recommendations regarding clinical uses relating to serum FLC levels or FLC ratio are based on results obtained with the validated serum FLC assay.

^hPresence/absence of clonal cells on immunohistochemistry is based upon the κ/λ ratio. An abnormal κ/λ ratio by immunohistochemistry requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is κ/λ of >4:1 or <1:2.

ⁱSpecial attention should be given to the emergence of a different monoclonal protein following treatment, especially in the setting of patients having achieved a conventional complete response, often related to oligoclonal reconstitution of the immune system. These bands typically disappear over time and in some studies have been associated with a better outcome. Also, appearance of monoclonal IgG κ in patients receiving monoclonal antibodies should be differentiated from the therapeutic antibody.

^jPlasmacytoma measurements should be taken from the CT portion of the PET/CT, or MRI scans, or dedicated CT scans where applicable. For patients with only skin involvement, skin lesions should be measured with a ruler. Measurement of tumor size will be determined by the SPD.

^kPositive immunofixation alone in a patient previously classified as achieving a complete response will not be considered progression. For purposes of calculating time to progression and progression-free survival, patients who have achieved a complete response and are MRD-negative should be evaluated using criteria listed for progressive disease. Criteria for relapse from a complete response or relapse from MRD should be used only when calculating disease-free survival.

^lIn the case where a value is felt to be a spurious result per physician discretion (eg, a possible laboratory error), that value will not be considered when determining the lowest value.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



MYELOMA THERAPY^{a-d}

Exposure to myelotoxic agents (including alkylating agents and nitrosoureas) should be limited to avoid compromising stem cell reserve prior to stem cell harvest in patients who may be candidates for transplants.

PRIMARY THERAPY FOR TRANSPLANT CANDIDATES
Preferred Regimens <ul style="list-style-type: none"> • Bortezomib/lenalidomide^e/dexamethasone (category 1) • Bortezomib/cyclophosphamide/dexamethasone^f
Other Recommended Regimens <ul style="list-style-type: none"> • Bortezomib/doxorubicin/dexamethasone (category 1) • Carfilzomib^{g,h}/lenalidomide^e/dexamethasone • Ixazomib/lenalidomide^e/dexamethasone (category 2B)
Useful In Certain Circumstances <ul style="list-style-type: none"> • Bortezomib/dexamethasone (category 1)ⁱ • Bortezomib/thalidomide/dexamethasone (category 1) • Cyclophosphamide/lenalidomide^e/dexamethasone • Lenalidomide^e/dexamethasone (category 1)ⁱ • Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide/bortezomib (VTD-PACE)

[See Evidence Blocks on MYEL-E \(EB-1\)](#)

^a Selected, but not inclusive of all regimens.

^b Herpes zoster prophylaxis for patients treated with proteasome inhibitors or daratumumab.

^c Subcutaneous bortezomib is the preferred method of administration.

^d Aspirin (81–325 mg) is recommended with immunomodulator-based therapy. Therapeutic anticoagulation is recommended for those at high risk for thrombosis.

^e Consider harvesting peripheral blood stem cells prior to prolonged exposure to lenalidomide.

^f Preferred initial treatment in patients with acute renal insufficiency. Consider switching to bortezomib/lenalidomide/dexamethasone after renal function improves.

^g Optimal dosing in this regimen has not been defined.

^h Can potentially cause cardiac and pulmonary toxicity, especially in elderly patients.

ⁱ Triplet regimens should be used as the standard therapy for patients with multiple myeloma; however, elderly or frail patients may be treated with doublet regimens.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

MYEL-E
1 OF 3



MYELOMA THERAPY^{a-d}

PRIMARY THERAPY FOR NON-TRANSPLANT CANDIDATES
Preferred Regimens <ul style="list-style-type: none"> • Bortezomib/lenalidomide/dexamethasone (category 1) • Lenalidomide/low-dose dexamethasone (category 1)^{i,j} • Bortezomib/cyclophosphamide/dexamethasone^f • Daratumumab^k/bortezomib/melphalan/prednisone (category 1)
Other Recommended Regimens <ul style="list-style-type: none"> • Carfilzomib^h/lenalidomide/dexamethasone • Carfilzomib^h/cyclophosphamide/dexamethasone • Ixazomib/lenalidomide/dexamethasone
Useful In Certain Circumstances <ul style="list-style-type: none"> • Bortezomib/dexamethasoneⁱ • Cyclophosphamide/lenalidomide/dexamethasone
MAINTENANCE THERAPY
Preferred Regimens <ul style="list-style-type: none"> • Lenalidomide^l (category 1)
Other Recommended Regimens <ul style="list-style-type: none"> • Bortezomib

[See Evidence Blocks on MYEL-E \(EB-1\)](#)

^a Selected, but not inclusive of all regimens.

^b Herpes zoster prophylaxis for patients treated with proteasome inhibitors or daratumumab.

^c Subcutaneous bortezomib is the preferred method of administration.

^d Aspirin (81–325 mg) is recommended with immunomodulator-based therapy. Therapeutic anticoagulation is recommended for those at high risk for thrombosis.

^f Preferred initial treatment in patients with acute renal insufficiency. Consider switching to bortezomib/lenalidomide/dexamethasone after renal function improves.

^h Can potentially cause cardiac and pulmonary toxicity, especially in elderly patients.

ⁱ Triplet regimens should be used as the standard therapy for patients with multiple myeloma; however, elderly or frail patients may be treated with doublet regimens.

^j Continuously until progression. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906-917.

^k May interfere with serological testing and cause false-positive indirect Coombs test. ([See MYEL-F](#))

^l There appears to be an increased risk for secondary cancers, especially with lenalidomide maintenance following transplant. The benefits and risks of maintenance therapy vs. secondary cancers should be discussed with patients.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

MYEL-E
2 OF 3

**NCCN Guidelines Version 3.2019**
Multiple Myeloma
NCCN Evidence Blocks™**MYELOMA THERAPY^{a-d,m}****THERAPY FOR PREVIOUSLY TREATED MULTIPLE MYELOMAⁿ****Preferred Regimens**

- Bortezomib/lenalidomide/dexamethasone
- Carfilzomib (twice weekly)^h/dexamethasone (category 1)ⁱ
- Carfilzomib (weekly)^h/dexamethasoneⁱ
- Carfilzomib^h/lenalidomide/dexamethasone (category 1)^o
- Daratumumab^p/bortezomib/dexamethasone (category 1)
- Daratumumab^p/lenalidomide/dexamethasone (category 1)
- Elotuzumab^q/lenalidomide/dexamethasone (category 1)^o
- Ixazomib^s/lenalidomide/dexamethasone (category 1)^o

Other Recommended Regimens

- Bendamustine/bortezomib/dexamethasone
- Bendamustine/lenalidomide/dexamethasone
- Bortezomib/liposomal doxorubicin/dexamethasone (category 1)
- Bortezomib/cyclophosphamide/dexamethasone
- Carfilzomib^h/cyclophosphamide/dexamethasone
- Cyclophosphamide/lenalidomide/dexamethasone
- Bortezomib/dexamethasone (category 1)ⁱ
- Daratumumab^{p,r}
- Daratumumab^p/pomalidomide^v/dexamethasone
- Elotuzumab/bortezomib/dexamethasone
- Elotuzumab/pomalidomide/dexamethasone^v
- Ixazomib^s/dexamethasoneⁱ
- Ixazomib/pomalidomide^w/dexamethasone
- Lenalidomide/dexamethasone^t (category 1)ⁱ
- Panobinostat^u/bortezomib/dexamethasone (category 1)
- Panobinostat^u/carfilzomib^{h,i}
- Panobinostat^u/lenalidomide/dexamethasone
- Pomalidomide^w/cyclophosphamide/dexamethasone
- Pomalidomide^w/dexamethasone^t (category 1)ⁱ
- Pomalidomide^w/bortezomib/dexamethasone
- Pomalidomide^w/carfilzomib^h/dexamethasone

Useful In Certain Circumstances

- Bendamustine
- Dexamethasone/cyclophosphamide/etoposide/cisplatin (DCEP)^x
- Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE)^x ± bortezomib (VTD-PACE)^x
- High-dose cyclophosphamide

^a Selected, but not inclusive of all regimens.^b Herpes zoster prophylaxis for patients treated with proteasome inhibitors or daratumumab.^c Subcutaneous bortezomib is the preferred method of administration.^d Aspirin (81–325 mg) is recommended with immunomodulator-based therapy. Therapeutic anticoagulation is recommended for those at high risk for thrombosis.^h Can potentially cause cardiac and pulmonary toxicity, especially in elderly patients.ⁱ Triplet regimens should be used as the standard therapy for patients with multiple myeloma; however, elderly or frail patients may be treated with doublet regimens.^m Consideration for appropriate regimen is based on the context of clinical relapse.ⁿ If a regimen listed on this page was used as a primary induction therapy and relapse is >6 mo, the same regimen may be repeated.^o Clinical trials with these regimens primarily included patients who were lenalidomide-naïve or with lenalidomide-sensitive multiple myeloma.^p May interfere with serological testing and cause false-positive indirect Coombs test. ([See MYEL-F](#))^q Indicated in combination with lenalidomide and dexamethasone for the treatment of patients who have received one to three prior therapies.^r Indicated for the treatment of patients who have received at least three prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and immunomodulatory agent.^s Indicated for the treatment of patients who have received at least one prior therapy.^t Consider single-agent lenalidomide or pomalidomide for steroid-intolerant individuals.^u Indicated for the treatment of patients who have received at least two prior regimens, including bortezomib and an immunomodulatory agent.^v Indicated for the treatment of patients who have received at least two prior therapies including an immunomodulatory agent and a proteasome inhibitor^w Indicated for the treatment of patients who have received at least two prior therapies including an immunomodulatory agent and a proteasome inhibitor and who have demonstrated disease progression on or within 60 days of completion of the last therapy.^x Generally reserved for the treatment of aggressive multiple myeloma.**Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).****All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.****[See Evidence Blocks on MYEL-E \(EB-2\)](#)****MYEL-E
3 OF 3**



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 3.2019

Multiple Myeloma

NCCN Evidence Blocks™

5					E = Efficacy of Regimen/Agent
4					S = Safety of Regimen/Agent
3					Q = Quality of Evidence
2					C = Consistency of Evidence
1					A = Affordability of Regimen/Agent
	E	S	Q	C	A

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

EVIDENCE BLOCKS FOR PRIMARY THERAPY FOR MULTIPLE MYELOMA

Primary Therapy for Transplant Candidates (assess for response after each cycle)	
Preferred Regimens	
Bortezomib/lenalidomide/dexamethasone	
Bortezomib/cyclophosphamide/dexamethasone	
Other Recommended Regimens	
Bortezomib/doxorubicin/dexamethasone	
Carfilzomib/lenalidomide/dexamethasone	
Ixazomib/lenalidomide/dexamethasone	
Useful in Certain Circumstances	
Bortezomib/dexamethasone	
Bortezomib/thalidomide/dexamethasone	
Cyclophosphamide/lenalidomide/dexamethasone	
Lenalidomide/dexamethasone	
Dexamethasone/thalidomide/cisplatin/doxorubicin/ cyclophosphamide/etoposide/bortezomib (VTD-PACE)	

Primary Therapy for Non-Transplant Candidates (assess for response after each cycle)	
Preferred Regimens	
Bortezomib/lenalidomide/dexamethasone	
Lenalidomide/low-dose dexamethasone	
Bortezomib/cyclophosphamide/dexamethasone	
Daratumumab/bortezomib/melphalan/prednisone	
Other Recommended Regimens	
Carfilzomib/lenalidomide/dexamethasone	
Carfilzomib/cyclophosphamide/dexamethasone	
Ixazomib/lenalidomide/dexamethasone	
Useful in Certain Circumstances	
Bortezomib/dexamethasone	
Cyclophosphamide/lenalidomide/dexamethasone	

Maintenance Therapy	
Preferred Regimens	
Lenalidomide	
Other Recommended Regimens	
Bortezomib	

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

MYEL-E
EB-1



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 3.2019

Multiple Myeloma

NCCN Evidence Blocks™

5				
4				
3				
2				
1				
E S Q C A				

E = Efficacy of Regimen/Agent
S = Safety of Regimen/Agent
Q = Quality of Evidence
C = Consistency of Evidence
A = Affordability of Regimen/Agent

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

EVIDENCE BLOCKS FOR THERAPY FOR PREVIOUSLY TREATED MULTIPLE MYELOMA

Preferred Regimens	
Bortezomib/lenalidomide/dexamethasone	
Carfilzomib (twice weekly)/dexamethasone	
Carfilzomib/lenalidomide/dexamethasone	
Daratumumab/bortezomib/dexamethasone	
Daratumumab/lenalidomide/dexamethasone	
Elotuzumab/lenalidomide/dexamethasone	
Ixazomib/lenalidomide/dexamethasone	

Useful in Certain Circumstances	
Bendamustine	
Dexamethasone/cyclophosphamide/etoposide/cisplatin (DCEP)	
Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE)	
Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide/bortezomib (VTD-PACE)	
High-dose cyclophosphamide	

Other Recommended Regimens			
Bendamustine/bortezomib/dexamethasone		Elotuzumab/pomalidomide/dexamethasone	
Bendamustine/lenalidomide/dexamethasone		Ixazomib/dexamethasone	
Bortezomib/liposomal doxorubicin/dexamethasone		Ixazomib/pomalidomide/dexamethasone	
Bortezomib/cyclophosphamide/dexamethasone		Lenalidomide/dexamethasone	
Carfilzomib/cyclophosphamide/dexamethasone		Panobinostat/bortezomib/dexamethasone	
Carfilzomib (weekly)/dexamethasone		Panobinostat/carfilzomib	
Cyclophosphamide/lenalidomide/dexamethasone		Panobinostat/lenalidomide/dexamethasone	
Bortezomib/dexamethasone		Pomalidomide/cyclophosphamide/dexamethasone	
Daratumumab		Pomalidomide/dexamethasone	
Daratumumab/pomalidomide/dexamethasone		Pomalidomide/bortezomib/dexamethasone	
Elotuzumab/bortezomib/dexamethasone		Pomalidomide/carfilzomib/dexamethasone	

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

MYEL-E
EB-2



SUPPORTIVE CARE TREATMENT FOR MULTIPLE MYELOMA

Bone Disease

- All patients receiving primary myeloma therapy should be given bisphosphonates (category 1)^a or denosumab.^b
 - ▶ A baseline dental exam is recommended.
 - ▶ Monitor for renal dysfunction with use of bisphosphonate therapy.
 - ▶ Monitor for osteonecrosis of the jaw.
- Use of bisphosphonates in smoldering or stage I disease preferably in the context of a clinical trial. These patients should have skeletal survey if clinically indicated.
- RT (See [Principles of Radiation Therapy \[MYEL-C\]](#))
- Orthopedic consultation should be sought for impending or actual long-bone fractures or bony compression of spinal cord or vertebral column instability.
- Consider vertebroplasty or kyphoplasty for symptomatic vertebral compression fractures.

Hypercalcemia

- Hydration, bisphosphonates (zoledronic acid preferred), denosumab, steroids, and/or calcitonin are recommended.

Hyperviscosity

- Plasmapheresis should be used as adjunctive therapy for symptomatic hyperviscosity.

Anemia

- [See NCCN Guidelines for Cancer- and Chemotherapy-Induced Anemia.](#)
- Consider erythropoietin for anemic patients.
- Type and screen should be performed before using daratumumab.

Infection

- [See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections.](#)
- Intravenous immunoglobulin therapy should be considered in the setting of recurrent life-threatening infection.
- The pneumococcal conjugate vaccine should be given followed by the pneumococcal polysaccharide vaccine one year later.
- *Pneumocystis jiroveci pneumonia* (PJP), herpes, and antifungal prophylaxis should be given if receiving high-dose dexamethasone regimen.
- Herpes zoster prophylaxis for all patients treated with proteasome inhibitors or daratumumab.

Renal Dysfunction

- Maintain hydration to avoid renal failure.
- Avoid use of NSAIDs.
- Avoid IV contrast.
- Perform plasmapheresis (category 2B).
- Consider renal biopsy if clinically indicated.
- Monitor for renal dysfunction with chronic use of bisphosphonates.

Coagulation/Thrombosis

- Aspirin (81–325 mg) is recommended with immunomodulator-based therapy. Therapeutic anticoagulation is recommended for those at high risk for thrombosis.
- [See NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease](#)

^aBoth pamidronate and zoledronic acid have shown equivalence in terms of reducing risk of skeletal-related events in randomized trials. In a recent MRC IX trial, in addition to benefits for bone health, zoledronic acid reduced mortality by 16% versus clodronic acid and extended median overall survival by 5.5 months. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial. *Lancet* 2010;376:1989-1999.

^bDenosumab is preferred in patients with renal insufficiency.

Note: For more information regarding the categories and definitions used for the NCCN Evidence Blocks™, see page [EB-1](#).

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

NCCN Categories of Preference

Preferred intervention: Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.

Other recommended intervention: Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.

Useful in certain circumstances: Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.



Table of Contents

Overview	MS-3	Maintenance Therapy	MS-27
Literature Search Criteria and Guidelines Update Methodology	MS-3	Treatment of Progressive or Relapsed Myeloma	MS-30
Diagnosis and Workup	MS-3	Supportive Care Treatment for Multiple Myeloma	MS-42
Additional Diagnostic Tests	MS-5	References	MS-45
Solitary Plasmacytoma	MS-7		
Primary Therapy for Solitary Plasmacytoma	MS-7		
Surveillance/Follow-up Tests for Solitary Plasmacytoma	MS-7		
Smoldering (Asymptomatic) Myeloma	MS-8		
Primary Therapy for Smoldering (Asymptomatic) Myeloma	MS-8		
Surveillance/Follow-up Tests for Smoldering (Asymptomatic) Myeloma	MS-8		
Active (Symptomatic) Multiple Myeloma	MS-9		
Primary Therapy for Active (Symptomatic) Multiple Myeloma	MS-9		
Monitoring After Primary Myeloma Therapy of Both Transplant and Non-Transplant Candidates	MS-21		
Stem Cell Transplants	MS-22		
Autologous Stem Cell Transplants	MS-22		
Tandem Stem Cell Transplants	MS-24		
Allogeneic Stem Cell Transplant	MS-26		
Follow-Up After Stem Cell Transplantation	MS-27		



Overview

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. MM accounts for about 1.8% of all cancers and slightly over 17% of hematologic malignancies in the United States.¹ Myeloma is most frequently diagnosed among people aged 65 to 74 years, with the median age being 69 years.² Myeloma is most frequently diagnosed among people aged 65 to 74 years, with the median age being 69 years.² The American Cancer Society has estimated 32,110 new myeloma cases in the United States in 2019, with an estimated 12,960 deaths.⁷

Newly diagnosed MM is typically sensitive to a variety of cytotoxic drugs. Although responses are typically durable, relapse is an expected part of the disease course and MM is not considered curable with current approaches. Treatment of MM has been rapidly evolving with the introduction of new classes and newer generation of drugs: immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies, and histone deacetylase (HDAC) inhibitors.^{3,4} Other emerging immunotherapy approaches such as chimeric antigen receptor (CAR) T-cell therapy and bi-specific T-cell engagers (BiTEs) appear quite promising and will further change the treatment landscape.

The NCCN Guidelines for Multiple Myeloma address diagnosis, treatment, and follow-up for patients with MM.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Multiple Myeloma, an electronic search of the PubMed database was performed to obtain key literature in MM published since the last update of this Discussion section, using the following search terms: Smoldering

Myeloma OR Multiple Myeloma. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.⁵

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The results of the PubMed search were examined for their potential relevance. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Any recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

Diagnosis and Workup

The initial diagnostic workup in all patients should include a history and physical examination and the following baseline blood studies and biological assessments to differentiate symptomatic and asymptomatic MM: a complete blood count (CBC) with differential and platelet counts; examination of peripheral blood smear; blood urea nitrogen (BUN); serum creatinine; creatinine clearance (calculated or measured directly) and serum electrolytes; serum calcium; albumin; lactate dehydrogenase (LDH); and beta-2 microglobulin.



Peripheral smear may show abnormal distribution of red blood cells such as the Rouleaux formation (red cells taking on the appearance of a stack of coins) due to elevated serum proteins.⁶ Increased BUN and creatinine indicate decreased kidney function, whereas LDH and beta-2 microglobulin levels reflect tumor cell characteristics. These tests are essential for R-ISS staging.

Serum and Urine Analysis: The monoclonal protein (M-protein) components in serum and urine are evaluated by the following urine and serum analyses.

Serum analysis includes quantitative immunoglobulin levels (IgG, IgA, and IgM); serum protein electrophoresis (SPEP); and serum immunofixation electrophoresis (SIFE) to obtain more specific information about the type of M-protein present. Assessing changes in levels of various proteins, particularly the M-protein, helps track disease progression and response to treatment. Urine analysis as a part of the initial diagnostic workup includes evaluating 24-hour urine for total protein; urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE).

Free Light-chain Assay: Use of serum free light-chain (FLC) assay along with SPEP and SIFE yields high sensitivity while screening for MM and related plasma cell disorders.⁷ Therefore, this assay is now included as a part of the initial diagnostic workup in the NCCN Guidelines for Multiple Myeloma. The serum FLC assay also has prognostic value in plasma cell disorders, including monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, active myeloma, immunoglobulin light chain amyloidosis, and solitary plasmacytoma.^{7,8} The serum FLC assay also allows for quantitative monitoring of patients with light chain amyloidosis and oligosecretory myeloma. In addition to all of the above, the FLC ratio is required for documenting stringent complete

response (sCR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria.⁹ The FLC assay cannot replace the 24-hour UPEP for monitoring patients with measurable urinary M-protein. Once the myeloma or M-protein is quantified, it is important to use the same test for serial studies to ensure accurate relative quantification.

Bone Marrow Evaluation: To evaluate bone marrow plasma cell infiltration, bone marrow aspiration and biopsy is recommended to detect quantitative and/or qualitative abnormalities of bone marrow plasma cells.

Radiographic Evaluation: To evaluate for lytic bone lesions, full skeleton radiographic survey or whole body low-dose CT is recommended.¹⁰⁻¹² The latter is more sensitive in identifying bone lesions and is the preferred method.

Cytogenetic Studies: Although MM may be morphologically similar, several subtypes of the disease have been identified at the genetic and molecular level. Bone marrow studies at initial diagnosis should include chromosome analysis by fluorescence in situ hybridization (FISH) performed with the plasma cells obtained from bone marrow aspiration. Metaphase cytogenetics may provide additional information. Specific chromosomal abnormalities have been identified in patients with MM involving translocations, deletions, or amplifications.

Deletion of 17p13 (the locus for the tumor-suppressor gene, *p53*) leads to loss of heterozygosity of *TP53* and is considered a high-risk feature in MM.¹³⁻¹⁵ Higher proportion of myeloma cells with the abnormality as well as mutation of the remaining allele significantly enhances the risk. Other high-risk chromosomal aberrations in MM are characterized by structural changes that include specific rearrangements involving the *IGH* gene (encoding immunoglobulin heavy chain), located at 14q32. Several subgroups of patients are identified on the basis of 14q32 translocations.



The main translocations are the t(11;14)(q13;q32), t(4;14)(p16;q32), t(14;16)(q32;q23), and t(14;20)(q32;q12). Several studies have confirmed that MM patients with t(4;14), t(14;16), and t(14;20) have a poor prognosis, while t(11;14) is believed to impart less risk.¹⁶⁻¹⁹ del(13q) is a common abnormality that is observed on FISH studies, but is a negative prognostic factor only when observed on metaphase cytogenetics.

Abnormalities of chromosome 1 are also among the frequent chromosomal alterations in MM.²⁰ The short arm is most often associated with deletions and the long arm with amplifications.²¹ Gains/amplification of 1q21 as well as 1p deletion increases the risk of MM progression and incidence of the amplification is higher in relapsed than in newly diagnosed patients.^{20,22}

Stratification of patients into various risk groups based on the chromosomal markers is being utilized by some centers for prognostic counseling, selection, and sequencing of therapy approaches.^{23,24}

According to the NCCN Multiple Myeloma Panel members, the FISH panel for prognostic estimation of plasma cells should, at minimum, examine for t(4;14), t(14;16), 17p13 deletions, and chromosome 1 amplification. The utility of this information is to determine biological subtype and for prognostic recommendations as well as candidacy for clinical trials.

Gene Expression Profiling: In addition to cytogenetic markers of prognosis, gene expression signatures may be capable of discerning prognosis and helping rational therapeutic decisions.^{25,26} Further understanding of the molecular subtypes of MM is emerging from the application of high-throughput genomic tools such as gene expression profiling (GEP).²⁷ With the currently available novel treatment approaches, a majority of patients with MM can now anticipate long-term disease

control. However, patients with cytogenetically and molecularly defined high-risk disease do not receive the same benefit from certain approaches as the low-risk patients and need alternative therapies. GEP can provide additional prognostic information and further refine risk stratification, help therapeutic decisions, and inform novel drug design and development. Several groups have identified and developed 15-gene, 70-gene, and 92-gene models based on GEP signatures of MM cells.²⁸⁻³⁰ Studies show that patients in the high-risk group based on the 15-gene,²⁸ 70-gene,²⁹ or 92-gene³⁰ models had shorter survival compared with the low-risk group. The NCCN Panel unanimously agreed that although GEP is not currently *routinely* used in clinical practice during diagnostic workup, GEP is a useful tool and may be helpful in selected patients to estimate the aggressiveness of the disease and individualize treatment.

Bone Marrow Immunohistochemistry and Flow Cytometry:

Immunohistochemistry and/or flow cytometry may be used to confirm presence of monoclonal plasma cells, and to more accurately quantify plasma cell involvement.³¹ The cytoplasm of abnormal plasma cells contain either kappa or lambda light chains, and predominance of one or the other light chain expressing plasma cells indicate clonality. Specific immunophenotypic profiles of the myeloma cells may have prognostic implications.³²

Additional Diagnostic Tests

The NCCN Multiple Myeloma Panel recommends additional tests that may be useful under some circumstances. These include whole body MRI³³ or whole body FDG PET/CT scan.¹² The majority of patients with active myeloma will have positive results on PET scan.^{34,35} Whole body FDG PET/CT and MRI scans are more sensitive than plain radiographs and are



indicated when symptomatic areas show no abnormality on routine radiographs. Whole body FDG PET/CT results after induction therapy and stem cell transplant (SCT) help in predicting prognosis of patients with symptomatic MM.³⁶⁻³⁸

A tissue biopsy may also be necessary to confirm the presence of plasmacytomas. Plasma cell proliferation assays may be helpful to identify the fraction of proliferating myeloma cell population.³⁹ Also, if amyloidosis is suspected, the diagnosis is established by following the recommendations outlined in the NCCN Guidelines for Systemic Light Chain Amyloidosis.

Serum viscosity should be evaluated when clinical symptoms of hyperviscosity are suspected, particularly in those with high levels of M-protein.

In selected patients with MM, allogeneic transplantation may be considered. In this approach, myeloablative or non-myeloablative/reduced-intensity therapy is administered with infusion of stem cells (ie, peripheral blood or bone marrow) obtained from a donor, preferably a human leukocyte antigen (HLA)-identical sibling. In such cases, the patient will need to be HLA-typed.

Based on the results of the clinical and laboratory evaluation discussed in previous sections, patients are initially classified as either having smoldering (asymptomatic) disease or active (symptomatic) disease. For definitions refer to *Definition of Multiple Myeloma (Smoldering and Active)* in the algorithm.

The IMWG recently updated the disease definition of MM to include biomarkers in addition to existing requirements of CRAB features.⁴⁰ The CRAB criteria that define MM include: hypercalcemia (>11.5 mg/dL), renal

insufficiency (creatinine >2 mg/dL or creatinine clearance <40 mL/min), anemia (hemoglobin <10 g/dL or 2 g/dL < normal), and presence of bone lesions. The IMWG has also clarified that presence of one or more osteolytic lesions seen on skeletal radiography, whole body MRI, or whole body FDG PET/CT fulfills the criteria for bone disease.⁴⁰ The MM-defining biomarkers identified by the IMWG include one or more of the following: ≥60% clonal plasma cells in the bone marrow; involved/uninvolved FLC ratio of 100 or more with the involved FLC being ≥100 mg/L; or MRI with more than one focal lesion (involving bone or bone marrow).⁴⁰

The criteria by the IMWG for smoldering (asymptomatic) patients include serum M-protein (IgG or IgA) ≥30 g/L and/or clonal bone marrow plasma cells 10% to 59% and absence of CRAB features, myeloma-defining events, or amyloidosis.⁴⁰ The updated IMWG diagnostic criteria for MM allow initiation of therapy before end-organ damage on the basis of specific biomarkers, and also allow the use of sensitive imaging criteria to diagnose MM, including whole body FDG PET/CT and MRI.⁴⁰ Recently, a study analyzed clinical and laboratory information from 421 patients with smoldering myeloma and identified monoclonal protein >2g/dL, FLC ratio of >20, and >20% plasma cells as important risk factors for progression. Patients with 2 or more of these features had a median time to progression of 29 months.⁴¹

Those with active myeloma can be staged using the International Staging System (ISS) or Durie-Salmon Staging System.⁴² The ISS is based on easily obtained laboratory measures (serum beta-2 microglobulin and serum albumin) and is easier to use than the Durie-Salmon Staging System for patients with previously untreated MM. The ISS has been recently revised to incorporate the serum LDH and high-risk FISH



abnormalities [t(4;14), t(14;16), 17p13 deletion] and is the preferred staging approach.⁴³

Solitary Plasmacytoma

The diagnosis of solitary plasmacytoma requires a thorough evaluation to rule out the presence of additional lesions or systemic disease, because many patients presumed to have solitary plasmacytomas are found to have occult disease. Solitary plasmacytomas are further categorized as osseous or extraosseous. Osseous plasmacytoma is defined as a plasmacytoma emanating from bone without other evidence of disease. Solitary plasmacytomas derived from soft tissue are termed extraosseous.⁴⁴ An analysis of the SEER database between 1992 and 2004 found that incidence of osseous plasmacytoma was 40% higher than extraosseous plasmacytoma ($P < .0001$).⁴⁵

Primary Therapy for Solitary Plasmacytoma

The treatment and follow-up options for osseous and extraosseous plasmacytomas are similar. Radiation therapy has been shown to provide excellent local control of solitary plasmacytomas.⁴⁶⁻⁵² The largest retrospective study (N = 258) included patients with solitary plasmacytoma (n = 206) or extramedullary plasmacytoma (n = 52).⁵³ Treatments included RT alone (n = 214), RT plus chemotherapy (n = 34), and surgery alone (n = 8). Five-year overall survival (OS) was 74%, disease-free survival was 50%, and local control was 85%. Patients who received localized RT had a lower rate of local relapse (12%) than those who did not (60%).⁵²

The optimal radiation dose for treatment of solitary plasmacytomas is not known. The dose used in most published papers ranges from 30 to 60 Gy.^{51,52,54}

For those patients with osseous plasmacytoma, the NCCN Panel recommends primary radiation therapy (40–50 Gy in 1.8–2.0 Gy/fraction) to the involved field followed by surgery if structurally unstable or if there are any issues related to neurologic compromise due to mass effect. For extraosseous plasmacytomas primary treatment is radiation therapy (40–50 Gy in 1.8–2.0 Gy/fraction)⁴⁹ to the involved field followed by surgery,⁵⁵ if necessary.

Surveillance/Follow-up Tests for Solitary Plasmacytoma

Follow-up and surveillance tests for both solitary plasmacytoma and extraosseous plasmacytoma consist of blood and urine tests. Serial and frequent measurements of M-protein are required to confirm disease sensitivity. The recommended follow-up interval for these patients is every 3 to 6 months; however, patients with soft tissue and head/neck plasmacytoma could be followed less frequently after initial 3-month follow-up. According to the NCCN Panel, one should consider using the same imaging modality used during the initial workup for the follow-up assessments.

The blood tests include CBC; serum chemistry for creatinine, albumin, and corrected calcium; serum quantitative immunoglobulins; and SPEP with SIFE as needed. Testing for serum FLC assay, LDH, and beta-2 microglobulin may be useful under some circumstances.

The urine tests include 24-hour urine assay for total protein, UPEP, and UIFE.

Bone marrow aspirate and biopsy, and imaging studies using whole body MRI or low-dose CT or whole body FDG PET/CT are recommended as clinically indicated. PET imaging may detect early bone marrow involvement in patients with solitary plasmacytoma.^{35,56,57} Imaging studies are recommended as clinically indicated.



If progression to myeloma occurs, then the patient should be re-evaluated as described in *Diagnosis and Workup*, and systemic therapy must be administered as clinically indicated.

Smoldering (Asymptomatic) Myeloma

Smoldering (asymptomatic) myeloma describes a stage of disease with no symptoms and no related organ or tissue impairment.⁵⁸ Patients with Durie-Salmon stage I myeloma with low amounts of M-protein without significant anemia, hypercalcemia, or bone disease would be included in this category. Patients with asymptomatic smoldering MM may have an indolent course for many years without therapy.

Primary Therapy for Smoldering (Asymptomatic) Myeloma

Patients with smoldering myeloma do not need primary therapy, as it may take many months to years before the disease progresses. The risk of transformation to symptomatic myeloma⁵⁹ in these patients is life-long and therefore should be followed closely.

A relatively small, randomized, prospective, phase III study by the PETHEMA group investigated whether early treatment with lenalidomide and dexamethasone in patients (n = 125) with smoldering myeloma, at high risk of progression to active MM, prolongs the time to progression.⁶⁰ The high-risk group in the study was defined using the following criteria: plasma cell bone marrow infiltration of at least 10% and/or a monoclonal component (defined as an IgG level of ≥ 3 g/dL, an IgA level of ≥ 2 g/dL, or a urinary Bence Jones protein level of >1 g per 24 hours); and at least 95% phenotypically aberrant plasma cells in the bone marrow infiltrate. The OS reported in the trial at 3 years was higher in the group treated with the lenalidomide and dexamethasone arm (94% vs. 80%; HR, 0.31; 95% CI, 0.10–0.91; $P = .03$).⁶⁰ At a median follow-up of 75 months (range, 27–

57 months), treatment with lenalidomide and dexamethasone delayed median time to progression to symptomatic disease compared to no treatment (time to progression was not reached in the treatment arm compared to 23 months in the observation arm; HR, 0.24; 95% CI, 0.14–0.41).⁶⁷ The high OS rate seen after 3 years was also maintained (HR, 0.43; 95% CI, 0.20–0.90). Recently, the data from the randomized ECOG E3A06 trial was presented at the 2019 ASCO Annual Meeting. Lenalidomide given until progression or toxicity versus observation for patients with smoldering myeloma showed a progression-free advantage. The median 3-year PFS was 91% with lenalidomide treatment versus 66% for those under observation. The NCCN Panel strongly recommends that smoldering patients with high-risk features should be encouraged to join a clinical trial.⁶²

According to the NCCN Panel, the flow cytometry-based high-risk criteria specified in the study is not uniformly available. Based on the criteria used in the trial, some patients with active myeloma were classified as having high-risk smoldering myeloma. The NCCN Panel strongly believes there is need to re-evaluate the definition of high-risk smoldering myeloma.⁴⁷ The panel believes that it is too early to begin treating *all* patients with smoldering myeloma at high risk (as defined in the trial) of progression to active MM with any anti-myeloma therapy. The NCCN Multiple Myeloma Panel recommends that patients with smoldering myeloma should initially be observed at 3- to 6-month intervals (category 1 recommendation) or strongly recommends enrolling eligible patients with smoldering myeloma in clinical trials.

Surveillance/Follow-up Tests for Smoldering (Asymptomatic) Myeloma

The surveillance/follow-up tests include CBC; serum chemistry for creatinine, albumin, corrected calcium, serum quantitative



immunoglobulins, SPEP, and SIFE; and serum FLC assay as clinically indicated. The urine tests include 24-hour urine assay for total protein, UPEP, and UIFE. Bone marrow aspirate and biopsy with FISH and multiparameter flow cytometry may be used as clinically indicated

Skeletal survey or whole body low-dose CT is recommended as clinically indicated. Bone marrow aspiration and biopsy and imaging studies with MRI and/or CT and/or whole body FDG PET/CT are recommended as clinically indicated.⁶³ PET imaging seems to reliably predict active myeloma; by virtue of FDG uptake, low-level smoldering myeloma is typically negative on the PET scan.³⁴ It can also assess the extent of active disease, detect extramedullary involvement, or evaluate treatment response.^{35,64-66} The NCCN Panel recommends considering using the same imaging modality used during the initial workup for the follow-up assessments.

Multiparameter flow cytometry is a newly available tool that can help individualize the follow-up/surveillance strategy for patients with smoldering myeloma. It measures abnormal cells in the bone marrow and provides information regarding the risk of progression to active myeloma. A high proportion of abnormal plasma cells within the bone marrow plasma cell compartment (>95%) has been shown to predict the risk of progression in patients with smoldering myeloma or MGUS, as has quantity and type of M-protein (non-IgG) and abnormal serum FLC assay.^{67,68} According to the NCCN Multiple Myeloma Panel members, multiple parameter flow cytometry information may be a useful consideration in the follow-up/surveillance plan of patients with smoldering myeloma. Since this test is not standardized or widely available, they recommend that it should only be performed in laboratories with experience.

If the disease progresses to symptomatic myeloma, then patients should be treated according to the guidelines for symptomatic MM.

Active (Symptomatic) Multiple Myeloma

Primary Therapy for Active (Symptomatic) Multiple Myeloma

Patients presenting with active (symptomatic) myeloma are initially treated with primary therapy and in selected patients, primary therapy is followed by high-dose chemotherapy with autologous SCT. Research into various primary regimens has focused on improving the response rates and depth of response in both transplant and non-transplant candidates. The NCCN Panel Members have noted that it is important to assess for response to primary therapy after every cycle of therapy.

Stem cell toxins, such as nitrosoureas or alkylating agents, may compromise stem cell reserve, and regimens with these agents (notably melphalan) should be avoided in patients who are potential candidates for SCT. Therefore, one of the first steps in evaluating patients with advanced MM is to determine whether they are candidates for high-dose therapy and transplant, based on age and comorbidities. However, it should be noted that advanced age and renal dysfunction are not absolute contraindications to transplant. Therefore, referral to a stem cell center to assess stem cell candidacy is important.

It is also important to consider supportive care for all patients at diagnosis. For example, 80% of patients have bone disease and up to 33% have renal compromise. PI-based regimens may be of value in patients with renal failure, and in those with certain adverse cytogenetic features.⁶⁹

Bone disease, renal dysfunction, and other complications such as hypercalcemia, hyperviscosity, and coagulation/thrombosis should be treated with appropriate adjunctive measures (see *Supportive Care Treatment for Multiple Myeloma* in this Discussion). In all patients, careful



attention to supportive care is critical to avoid early complications that may compromise therapeutic outcome.

The page titled *Myeloma Therapy* in the algorithm has a list of primary therapy regimens recommended by the NCCN Multiple Myeloma Panel members for transplant and non-transplant candidates and also lists drugs recommended for maintenance therapy. The list is selected and is not inclusive of all regimens. The NCCN Multiple Myeloma Panel has categorized all myeloma therapy regimens as: “preferred,” “other recommended,” or “useful under certain circumstances.”

The purpose of classifying regimens as such is to convey the sense of the panel regarding the relative efficacy and toxicity of the regimens. Factors considered by the panel include evidence, efficacy, toxicity, pre-existing comorbidities such as renal insufficiency, and in some cases access to certain agents.

The NCCN Panel prefers 3-drug regimens over 2-drug regimens as the standard of care for primary treatment of myeloma. This is based on improved response rates, depth of response, and rates of progression-free survival (PFS) or OS seen with 3-drug regimens in clinical trials. However, the panel notes that doublets could be used if a patient is elderly and/or frail and unable to tolerate a 3-drug regimen.

Prophylaxis with aspirin (81–325 mg) is recommended for those receiving an IMiD-based therapy. An anticoagulation agent is recommended for patients receiving an IMiD-based therapy and who are at high risk for thrombosis.

Prophylactic antiviral therapy is recommended for all patients receiving PI-based therapies.^{70,71} This is because impaired lymphocyte function that

results from MM and/or its treatment-related myelosuppression may lead to reactivation of herpes simplex infection or herpes zoster.⁷¹⁻⁷⁴

Carfilzomib can potentially cause cardiac and pulmonary toxicities.⁷⁵ Careful assessment before initiating treatment with carfilzomib and close monitoring during treatment is recommended.⁷⁵

Preferred Primary Therapy Regimens for Transplant Candidates

Bortezomib-based 3-drug regimens have been listed as preferred primary therapy options for patients who are SCT eligible. These include bortezomib/lenalidomide/dexamethasone, bortezomib/doxorubicin/dexamethasone, and bortezomib/cyclophosphamide/dexamethasone.

The NCCN Panel has noted that subcutaneous administration is the preferred route for bortezomib. This is based on the results of the MMY-3021 trial. The trial randomized 222 patients to single-agent bortezomib administered either by the conventional intravenous (IV) route or by subcutaneous route.⁷⁶ The findings from the study demonstrate non-inferior efficacy with subcutaneous versus IV bortezomib with regard to the primary endpoint (overall response rate [ORR] after 4 cycles of single-agent bortezomib). Consistent results were shown with regard to secondary endpoints.⁷⁶ The results showed no significant differences in terms of time to progression or in one-year OS between groups.^{76,77} However, patients receiving bortezomib subcutaneously had a significant reduction in peripheral neuropathy. The panel recommends herpes prophylaxis in patients receiving bortezomib therapy.

The NCCN Multiple Myeloma Panel recommends harvesting peripheral blood stem cells early in the course of primary treatment, preferably after 3 to 4 cycles of initial therapy.

***Bortezomib/Lenalidomide/Dexamethasone***

Phase II and III studies results have shown that primary therapy with bortezomib/lenalidomide/dexamethasone is active and well tolerated in all newly diagnosed patients with MM, transplant eligible as well as transplant ineligible.⁷⁸⁻⁸⁰

In the first phase I/II prospective study of lenalidomide/bortezomib/dexamethasone in patients with newly diagnosed MM, the rate of partial response (PR) was 100%, with 74% very good partial response (VGPR) or better and 52% complete response (CR)/near CR.⁷⁸ The benefits of bortezomib/lenalidomide/dexamethasone as primary therapy were also seen in the results of the phase II IFM 2008 trial⁸⁰ and phase II EVOLUTION trial.⁷⁹ In the phase II IFM 2008 trial, patients received bortezomib, lenalidomide, and dexamethasone as induction therapy followed by SCT.⁸⁰ Patients subsequently received two cycles of bortezomib/lenalidomide/dexamethasone as consolidation cycles and 1-year lenalidomide maintenance. VGPR rate or better at the completion of induction was 58%.⁸⁰ After transplantation and consolidation therapy the rate of VGPR or better was 70% and 87%, respectively.⁸⁰ The phase II EVOLUTION trial was designed to examine the tolerability and efficacy of combining bortezomib/cyclophosphamide/lenalidomide/dexamethasone versus bortezomib/lenalidomide/dexamethasone versus bortezomib/cyclophosphamide/dexamethasone in a randomized multicenter setting.⁷⁹ The ORR after primary treatment with bortezomib/lenalidomide/dexamethasone followed by maintenance with bortezomib was 85% (51% ≥ VGPR and 24% CR) and corresponding one-year PFS was 83% in the bortezomib/lenalidomide/dexamethasone arm.⁷⁹

This triplet was compared to lenalidomide/dexamethasone in the multicenter phase III SWOG S077 trial.⁸⁷ Patients (n = 525) with previously untreated MM were randomly assigned to receive 6 months of induction therapy with either bortezomib/lenalidomide/dexamethasone (N = 264) or lenalidomide/dexamethasone (N = 261), each followed by maintenance therapy with lenalidomide/dexamethasone until progression or unacceptable. The triple-drug regimen group had significantly longer PFS (43 months vs. 30 months; HR, 0.712; 96% CI, 0.56–0.906) and improved median OS (75 months vs. 64 months; HR, 0.709; 95% CI, 0.524–0.959).⁸⁷ As expected, ≥ grade 3 neuropathy was more frequent in the bortezomib-containing arm (24% vs. 5%; *P* < .0001) as bortezomib was administered intravenously in this study.⁸⁷

Based on the significant improvement in PFS and OS seen with bortezomib/lenalidomide/dexamethasone, the NCCN Panel included this regimen as a category 1, preferred option for primary treatment of transplant-eligible patients with MM.

Bortezomib/Cyclophosphamide/Dexamethasone

Data from 3 phase II studies involving newly diagnosed patients with MM have demonstrated high response rates with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as primary treatment.^{79,82,83} The trial by Reeder et al carried out in the United States and Canada demonstrated an ORR of 88% including a VGPR or greater of 61% and 39% CR/near CR with CyBorD as the primary regimen.⁸² The depth of response seen after primary treatment was maintained after transplant in those who underwent transplantation (70% rates of CR/near CR; rate of at least VGPR or better was 74%).⁸² According to the long-term follow-up analysis, the 5-year PFS and OS rates were 42% (95% CI, 31–57) and 70% (95% CI, 59–82).⁸⁴



Analysis of the German DSMM XIa study also demonstrated high responses with CyBorD as primary treatment (ORR was 84%, with 71.5% PR rate and 12.5% CR rate). High response rates were seen in patients with unfavorable cytogenetics.⁸³

In the updated results of the phase II EVOLUTION study, primary treatment with CyBorD demonstrated an ORR of 75% (22% CR and 41% ≥ VGPR), and the one-year PFS rate was 93%.⁷⁹

Based on data from these and other phase II studies, the NCCN Multiple Myeloma Panel has now included the combination of cyclophosphamide/bortezomib/dexamethasone to the list of primary treatment available for transplant candidates. This is a preferred option, especially in patients with acute renal insufficiency. According to the NCCN Panel, one can consider switching to bortezomib/lenalidomide/dexamethasone after renal function improves.

Twice-weekly bortezomib can be associated with toxicities that may limit efficacy caused by treatment delays or discontinuation. Therefore, Reeder et al modified the regimen to a once-weekly schedule of bortezomib.⁸⁵ In the study, patients treated with weekly bortezomib achieved responses similar to the twice-weekly schedule (ORR, 93% vs. 88%; VGPR, 60% vs. 61%). In addition, they experienced less grade 3/4 adverse events (37%/3% vs. 48%/12%). Fewer dose reductions of bortezomib/dexamethasone were required in the modified schedule and neuropathy rates were the same in both cohorts, even though the total bortezomib dose per cycle was higher in the weekly versus the twice-weekly schedule (6.0 mg/m² vs. 5.2 mg/m²).⁸⁵

Other Recommended Primary Therapy Regimens for Transplant Candidates

Bortezomib/Doxorubicin/Dexamethasone

The updated results from the HOVON-65/GMMG-HD4 group phase III trial of newly diagnosed patients with stage II/III MM demonstrated high response rates after primary therapy with bortezomib/doxorubicin/dexamethasone versus vincristine/doxorubicin/dexamethasone (VAD), and this superior response rate (CR + near CR was 31% vs. 15%; $P < .001$) was maintained even after SCT with significantly higher ORR.⁸⁶ No unexpected toxicities occurred, and del(13q) did not have a significant impact on response. Response rates improved with bortezomib maintenance (34% vs. 49%; $P < .001$).⁸⁶ After a median follow-up of 41 months, PFS in patients treated with bortezomib/doxorubicin/dexamethasone as primary therapy followed by SCT and bortezomib maintenance was 35 months versus 28 months in patients treated with VAD followed by SCT and maintenance with thalidomide. Patients treated with bortezomib/doxorubicin/dexamethasone had a significantly better PFS (HR, 0.75; 95% CI, 0.62–0.90; $P = .002$).⁸⁶ The OS was also found to be better in the bortezomib, doxorubicin, and dexamethasone arm (HR, 0.77; 95% CI, 0.60–1.00; $P = .049$). In high-risk patients presenting with increased creatinine more than 2 mg/dL, bortezomib significantly improved PFS from a median of 13 months to 30 months (HR, 0.45; 95% CI, 0.26–0.78; $P = .004$) and OS from a median of 21 months to 54 months (HR, 0.33; 95% CI, 0.16–0.65; $P < .001$). A benefit in terms of increased PFS was also observed in patients with deletion of 17p13.⁸⁶ The rate of grade 2 to 4 peripheral neuropathy was higher in those treated with the bortezomib-containing regimen versus VAD (40% vs. 18%). In addition, newly developed grade 3 to 4 peripheral neuropathy occurred in 8% of patients during thalidomide maintenance and 5% of patients during bortezomib maintenance.⁸⁶

Based on data from the HOVON-65/GMMG-HD4 trial and the uniform consensus among the NCCN Multiple Myeloma Panel members,



bortezomib/doxorubicin/dexamethasone is a category 1 option for primary therapy for transplant-eligible patients with MM.

Carfilzomib/Lenalidomide/Dexamethasone

Carfilzomib is a second-generation PI that binds highly selectively and irreversibly to the proteasome. It is administered intravenously. Carfilzomib has demonstrated anti-myeloma activity in patients with relapsed and/or refractory MM with an acceptable tolerability profile, including limited neuropathy after prolonged treatment.^{87,88}

The safety and efficacy of carfilzomib in combination with lenalidomide and dexamethasone, as *primary* therapy for patients with MM, were evaluated in two single-arm trials.

First, a multicenter phase I/II trial evaluated the combination of carfilzomib, lenalidomide, and dexamethasone in newly diagnosed patients with MM.⁸⁹ In this trial, patients (n = 53) received carfilzomib with lenalidomide and low-dose dexamethasone. After 4 cycles, stem cells were collected from eligible patients.⁸⁹ Out of 35 patients from whom stem cells were collected, 7 proceeded to transplantation, and the remainder continued with carfilzomib/lenalidomide/dexamethasone.⁸⁹ With median follow-up of 13 months, 24-month PFS was estimated at 92%. The most common grade 3 and 4 toxicities in ≥10% of patients included hypophosphatemia (25%), hyperglycemia (23%), anemia (21%), thrombocytopenia (17%), and neutropenia (17%). Peripheral neuropathy was limited to grade 1/2 (23%).⁸⁹

Another phase II trial also evaluated the same regimen (carfilzomib in combination with lenalidomide and dexamethasone) in newly diagnosed patients (n = 45) with MM. After 8 cycles of treatment, patients with SD received up to 24 cycles of lenalidomide 10 mg/d on days 1 to 21.⁹⁰ Thirty-

eight patients were evaluable for response and toxicity. After a median follow-up of 10 months, PFS was 83.3%. Twenty-five patients completed 8 cycles of the carfilzomib, lenalidomide, and dexamethasone regimen, of which 24 continued to lenalidomide therapy and 1 patient opted to exit the study after initial therapy. The most common non-hematologic and hematologic toxicities (≥ grade 3) in >10% of patients included electrolyte disturbances (18%), liver function test elevation (13%), rash/pruritus (11%), fatigue (11%), lymphopenia (63%), anemia (16%), leukopenia (13%), and thrombocytopenia (11%).⁹¹

The results of a phase 2 trial multicenter study of carfilzomib/lenalidomide/dexamethasone in newly diagnosed transplant-eligible patients (n = 76) showed that CR or better was seen in 86% of patients at the end of 18 cycles for carfilzomib/lenalidomide/dexamethasone plus autologous SCT compared to 59% for carfilzomib/lenalidomide/dexamethasone and no autologous SCT. The 3-year PFS was 80% for carfilzomib/lenalidomide/dexamethasone alone and 86% for carfilzomib/lenalidomide/dexamethasone with autologous SCT patients. The 3-year OS was 96% for carfilzomib/lenalidomide/dexamethasone alone and 95% for carfilzomib/lenalidomide/dexamethasone with autologous SCT. The grade ≥3 adverse events, with autologous SCT versus autologous SCT, included lymphopenia (25% vs. 45%), neutropenia (25% vs. 30%), and infection (16% vs. 8%). In the carfilzomib/lenalidomide/dexamethasone with autologous SCT, the cardiac adverse events were 4% for all grades (0% grade 3/4), hypertension was 16% (4% grade 3/4), and dyspnea was 32% (3% grade 3/4).⁹²

Based on the data from the above phase II studies, the NCCN Panel has included the carfilzomib, lenalidomide, and dexamethasone regimen as an option for primary treatment of transplant-eligible patients with MM. A phase III trial by the ECOG-ACRIN Cancer Research Group comparing



carfilzomib/lenalidomide/dexamethasone to bortezomib/lenalidomide/dexamethasone is currently recruiting patients (Clinical Trial ID: NCT01863550). The NCCN Panel strongly encourages participation in clinical trial.

Ixazomib/Lenalidomide/Dexamethasone

Ixazomib is an oral PI that was approved by the FDA in combination with lenalidomide and dexamethasone for the treatment of patients with MM who have received at least one prior therapy.

In a phase I/II trial, Kumar et al studied an all-oral combination of ixazomib/lenalidomide/dexamethasone in patients with newly diagnosed MM.⁹³ The results of this trial show that the regimen was well tolerated and active in the study population. Out of the 64 patients in whom the response could be evaluated, 37 (58%; 95% CI, 45–70) had a VGPR or better. Grade 3 or higher adverse events related to any drug in the combination were reported in 41 (63%) patients. These included skin and subcutaneous tissue disorders (11 patients, 17%), neutropenia (8 patients, 12%), and thrombocytopenia (5 patients, 8%); drug-related peripheral neuropathy of grade 3 or higher occurred in 4 (6%) patients.

Based on these phase II results and the fact that the combination of other PIs (bortezomib or carfilzomib) in combination with lenalidomide/dexamethasone have been shown to be as effective as primary therapy in newly diagnosed MM,^{87,89-91,94} the NCCN Panel has included ixazomib/lenalidomide/dexamethasone as an option (category 2B) for treatment of patients with newly diagnosed MM. An ongoing phase III trial is evaluating ixazomib/lenalidomide/dexamethasone versus lenalidomide/dexamethasone (Clinical trial ID: NCT01850524).

Regimens Useful Under Certain Circumstances for Transplant Candidates

While triple-drug regimens remain the preferred primary therapy option for patients with MM, selected patients such as those who are elderly or frail may be initially treated with regimens containing two drugs such as bortezomib/dexamethasone or lenalidomide/dexamethasone; a third drug could be added when the patient's condition improves.

Bortezomib/Dexamethasone

In the IFM cooperative group trial, 482 patients eligible for transplant were randomized to one of the following 4 primary therapy arms: VAD (n = 121) alone; VAD plus consolidation therapy with dexamethasone/cyclophosphamide, etoposide/cisplatin (DCEP; n = 121); bortezomib/dexamethasone (n = 121); or bortezomib/dexamethasone plus consolidation with DCEP (n = 119).⁹⁵ The primary endpoint was assessing response rate after primary therapy. The investigators evaluated the response according to modified European Group for Blood and Marrow Transplantation (EBMT) criteria,⁹⁶ including additional categories of near CR (CR but immunofixation-positive)⁹⁷ and VGPR (serum M-protein reduction ≥90%; urine light chain <100 mg/24 hours).⁹ After primary therapy, the ORR (78.5% vs. 62.8%) and the rates of CR/near CR (14.8% vs. 6.4%) and VGPR (37.7% vs. 15.1%) were significantly higher with bortezomib/dexamethasone versus VAD.⁹⁵ At a median follow-up of 32.2 months, median PFS was modestly but not statistically significantly prolonged compared to VAD (36.0 months vs. 29.7 months).⁹⁵ Use of DCEP as consolidation therapy after primary therapy did not have a significant impact on the rates of response.⁹⁵ The bortezomib/dexamethasone regimen was equally effective in patients with high-risk MM, including those with ISS stage III disease and poor-risk cytogenetic abnormalities. The incidence of severe adverse events



reported was similar between the two groups. Hematologic toxicity and deaths related to toxicity were more frequent with VAD versus bortezomib/dexamethasone. The rates of grade 2 (20.5% vs. 10.5%) and grades 3 to 4 (9.2% vs. 2.5%) peripheral neuropathy during induction through first transplantation were significantly higher with bortezomib/dexamethasone compared to VAD.⁹⁵

The IFM conducted a phase III randomized trial comparing bortezomib/dexamethasone with a combination of reduced doses of bortezomib and thalidomide plus dexamethasone.⁹⁸ The response rates achieved in the comparing bortezomib/dexamethasone arm seen in this study match those described in previous trials comparing VAD with bortezomib and dexamethasone.⁹⁵

Patients with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and OS. A study analyzed a large series of patients (<65 years) with newly diagnosed transplant-eligible MM treated and t(4;14) or del(17p) treated with bortezomib/dexamethasone versus VAD as primary therapy before treatment.⁶⁹ The analysis demonstrated that bortezomib improves the prognosis (in terms of both EFS and OS; $P < .001$ and $P < .001$, respectively) of patients with t(4;14) compared with patients treated with VAD primary therapy.⁶⁹

Based on these data and the uniform consensus among the NCCN Multiple Myeloma Panel members, bortezomib/dexamethasone is listed as a category 1 primary therapy option for transplant-eligible patients with MM under the category “useful under certain circumstances” because, as mentioned above, triple-drug regimens are preferred as primary therapy for transplant-eligible patients with MM. However, those with comorbid conditions such as with renal insufficiency may be treated with the

bortezomib/dexamethasone doublet initially and a third drug could be added when renal insufficiency or overall condition improves.

Cyclophosphamide/Lenalidomide/Dexamethasone

The efficacy and tolerability of cyclophosphamide/lenalidomide/dexamethasone in newly diagnosed patients was demonstrated in a phase II study. Of the 53 patients enrolled in the trial, 85% had a PR or better including VGPR in 47%. The median PFS was 28 months (95% CI, 22.7–32.6) and at 2 years the OS was 87% (95% CI, 78–96).⁹⁹

The NCCN Panel included cyclophosphamide/lenalidomide/dexamethasone as a primary therapy option for transplant-eligible patients with MM under the category “useful under certain circumstances” (category 2A).

Lenalidomide/Dexamethasone

Lenalidomide is a potent analogue of thalidomide. Like thalidomide, it is believed to attack multiple targets in the microenvironment of the myeloma cell, producing apoptosis and inhibition of angiogenesis and cytokine circuits, among others. Lenalidomide received approval from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory MM in combination with dexamethasone. Lenalidomide and dexamethasone have also been investigated as primary therapy. The phase III randomized controlled study, S0232, by Southwest Oncology Group (SWOG) compared dexamethasone single agent with lenalidomide and dexamethasone for patients newly diagnosed with MM.¹⁰⁰ There were 198 patients enrolled; upon disease progression, patients on the dexamethasone arm were allowed to cross over to the open-label lenalidomide and dexamethasone arm. Participants with progressive disease (PD) on lenalidomide and dexamethasone (initially or after crossover) were removed from the protocol. Due to inferior efficacy of



dexamethasone alone and concern of combining high-dose dexamethasone with lenalidomide, the data safety monitoring committee permanently closed enrollment in this trial.¹⁰⁷ At the time the trial was closed, at the end of one year, the lenalidomide plus dexamethasone arm showed improved CR rate compared to dexamethasone alone (22.1% vs. 3.8%).¹⁰⁰ At 3 years, PFS remained superior for lenalidomide and dexamethasone: 52% versus 32%.¹⁰² The OS was not different between the two arms. The 1-, 2-, and 3-year OS for lenalidomide and dexamethasone were 94%, 87%, and 79% versus 88%, 78%, and 73% for dexamethasone.

E4A03 was an open-label trial, with 445 newly diagnosed patients with MM randomly assigned to high-dose or low-dose dexamethasone regimens. The response was superior with high-dose dexamethasone. One hundred sixty-nine (79%) of 214 patients receiving high-dose therapy and 142 (68%) of 205 patients receiving low-dose therapy had CR or PR within 4 cycles.¹⁰³ At 1-year interim analysis, OS was 96% in the low-dose dexamethasone group compared with 87% in the high-dose group ($P = .0002$); 2-year OS was 87% versus 75%, respectively.

Fifty-two percent of patients on the high-dose regimen compared with 35% on the low-dose regimen had grade 3 or worse toxic effects in the first 4 months, including deep vein thrombosis (DVT) (26% vs. 12%); infections including pneumonia (16 vs. 9%); and fatigue (15% vs. 9%).

The effect of SCT and outcome of patients who continued the primary therapy in either group was analyzed at the end of 3 years.¹⁰³ The 3-year OS of patients who received 4 cycles of primary treatment with either dose followed by autologous SCT was 92%, suggesting that lenalidomide and dexamethasone is a reasonable choice for primary therapy before SCT.

However, it should be noted that the choice to proceed to SCT was not randomized but based on physician and patient preference.¹⁰³

The incidence of DVT is low with single-agent lenalidomide or lenalidomide plus low-dose dexamethasone, but risk rises when combined with high-dose dexamethasone. According to a recent report, patients treated with lenalidomide and high-dose dexamethasone that developed a venous thromboembolism (VTE) did not experience shorter OS or time to progression.¹⁰⁴ Prophylactic anticoagulation is recommended in patients receiving this therapy.^{70,105}

A decrease in CD34-positive cells collected after prolonged lenalidomide treatment has been reported.^{106,107} Guidelines by the IMWG suggest that patients treated with lenalidomide and dexamethasone should have stem cells collected within the first 4 cycles of therapy.¹⁰⁸ This inability to collect stem cells may be overcome by chemo-mobilization.¹⁰⁹ Addition of plerixafor can also allow stem cell mobilization when conventional mobilization methods fail.^{110,111}

Lenalidomide/dexamethasone is listed as a category 1 primary treatment option in the NCCN Guidelines under the category “useful under certain circumstances,” noting that triple-drug regimens are preferred as primary therapy for transplant-eligible patients with MM. However, elderly or frail patients may be treated with doublet regimens. The panel recommends appropriate thromboprophylaxis for patients receiving this therapy.

Bortezomib/Thalidomide/Dexamethasone

Thalidomide attacks multiple targets in the microenvironment of the myeloma cell, producing apoptosis, inhibition of angiogenesis, and cytokine circuits, among others. The GIMEMA Italian Multiple Myeloma



Network reported results of a phase III trial investigating bortezomib/thalidomide/dexamethasone (N = 241) versus thalidomide/dexamethasone (N = 239) as primary therapy, followed by tandem autologous SCT with high-dose melphalan and then consolidation therapy with the same primary regimen.¹¹² The addition of bortezomib to thalidomide and dexamethasone significantly improved ORR after primary treatment. After primary therapy, CR/near CR was achieved in 73 patients (31%; 95% CI, 25.0–36.8) receiving bortezomib/thalidomide/dexamethasone, and 27 patients (11%; 95% CI, 7.3–15.4) receiving thalidomide/dexamethasone.¹¹² Rates of CR/near CR and VGPR or better continued to be significantly higher in the bortezomib/thalidomide/dexamethasone group than in the thalidomide/dexamethasone group after the first and second autologous SCT and subsequent consolidation therapy.¹¹² Patients receiving the bortezomib-containing regimen experienced grade 3/4 peripheral neuropathy.

Data from a single-institution retrospective study are similar to the interim data from the GIMEMA trial.¹¹³ The findings of this analysis demonstrate that ORR after primary therapy with bortezomib/thalidomide/dexamethasone was 94% of the patients (32 of 34 patients showed some response, including a VGPR rate ≥56%).¹¹³

The results of the randomized phase III trial by the Spanish Myeloma Group (PETHEMA/GEM) also demonstrated a significantly higher CR rate with bortezomib/thalidomide/dexamethasone as primary therapy overall (35% vs. 14%, $P = .001$) and in patients with high-risk cytogenetics (35% vs. 0%, $P = .002$).¹¹⁴ The CR rate continued to be significantly higher after autologous SCT (46% vs. 24%) in patients treated with

bortezomib/thalidomide/dexamethasone versus thalidomide/dexamethasone as primary therapy.¹¹⁴

The phase III IFM 2013-04 trial is evaluating 4 cycles of CyBorD versus 4 cycles of bortezomib/thalidomide/dexamethasone as induction therapy before autologous SCT in patients (N = 340) with newly diagnosed MM.¹¹⁵ The results reported during the 2015 ASH meeting show that patients who received bortezomib/thalidomide/dexamethasone as induction therapy achieved higher ORR (92.3%) compared with those who received CyBorD (84%). Those who received bortezomib/thalidomide/dexamethasone had significantly greater VGPR ($P = .04$) and PR ($P = .02$) rates.¹¹⁵ The hematologic toxicity was greater in the CyBorD arm; however, higher rates of peripheral neuropathy were reported in the bortezomib/thalidomide/dexamethasone arm.¹¹⁵

No significant difference in OS was observed in any of the trials with bortezomib/thalidomide/dexamethasone. A longer follow-up period is required. The panel recommends appropriate thromboprophylaxis for patients receiving this therapy. Bortezomib/thalidomide/dexamethasone is listed as a primary treatment option (category 1) under the category “useful under certain circumstances.” Thalidomide is not widely used in the United States; however, it is more easily available and affordable in other resource-constrained parts of the world.

Bortezomib, Dexamethasone, Thalidomide, Cisplatin, Doxorubicin, Cyclophosphamide, and Etoposide (VTD-PACE)

The total therapy 3 (TT3) trial evaluated induction therapy with the multi-agent regimen, VTD-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide) prior to high-dose melphalan-based tandem auto-transplants and later as consolidation



therapy.¹⁷⁶ This regimen is a potent combination of new agents as well as traditional chemotherapy agents.

This regimen is listed under the category “useful under certain circumstances.” According to the NCCN Panel, VTD-PACE could be an option for newly diagnosed patients presenting with high-risk and aggressive extramedullary disease or plasma cell leukemia.

Preferred Primary Therapy Regimens for Non-Transplant Candidates

Many of the regimens described above for transplant candidates are also options for non-transplant candidates. As in transplant-eligible patients, 3-drug regimens are preferred by the NCCN Panel as these regimens have shown to induce higher response rates and depth of response in clinical trials. The 2-drug regimens are reserved for elderly and/or frail patients. The list of preferred options for non-transplant candidates includes: bortezomib/cyclophosphamide/dexamethasone, bortezomib/lenalidomide/dexamethasone, and lenalidomide/low-dose dexamethasone.

Bortezomib/Lenalidomide/Dexamethasone

Phase II study results (discussed in the transplant setting) have shown that primary therapy with bortezomib/lenalidomide/dexamethasone is active and well tolerated in all newly diagnosed patients with MM regardless of autologous SCT status.⁷⁸

The randomized phase III SWOG S0777 trial (discussed in the transplant setting), comparing bortezomib/lenalidomide/dexamethasone to lenalidomide/dexamethasone as induction therapy without an intent of immediate transplantation, reported superior results with the 3-drug regimen.⁸⁷ The NCCN Panel included the bortezomib/lenalidomide/dexamethasone regimen as a category 1, preferred option for patients with MM not eligible for SCT.

Lenalidomide/Low-dose Dexamethasone

The results of the SWOG SO232 trial¹⁰⁰ that included transplant-ineligible patients and the ECOG E4A03 trial¹⁰³ that included elderly patients with MM demonstrate that lenalidomide in combination with low-dose dexamethasone is a well-tolerated and effective regimen for these groups of patients. In the ECOG E4A03 trial the OS rate was significantly higher in the lenalidomide plus low-dose dexamethasone arm compared with the lenalidomide plus high-dose dexamethasone arm (also discussed under *Preferred Primary Therapy Regimens for Transplant Candidates*).¹⁰³ The inferior survival outcome seen with high-dose dexamethasone was greatest in patients aged 65 years and older. At 2 years, patients who did not proceed to transplant had an OS rate of 91% with lenalidomide and low-dose dexamethasone.¹⁰³

The international, multicenter trial (FIRST trial) evaluated efficacy and safety of lenalidomide/dexamethasone given continuously or for 72 weeks with melphalan/prednisone/thalidomide (MPT) in elderly (n = 1623)

transplantation-ineligible patients with newly diagnosed MM.¹⁷⁷ The primary endpoint of this trial was PFS, and secondary endpoints were OS and adverse events, including the incidence of secondary malignancies. After a median of 37 months of follow-up, the risk of progression or death was reduced by 28% in patients receiving continuous lenalidomide/dexamethasone versus MPT (HR, 0.72; 95% CI, 0.61–0.85; $P < .001$).¹⁷⁷ Continuous lenalidomide/dexamethasone also reduced the risk of progression or death compared with 18 cycles of lenalidomide/dexamethasone (HR, 0.70; 95% CI, 0.89–1.20; $P = .70$). In the interim analysis, an OS benefit was seen in the



lenalidomide/dexamethasone arm versus MPT (HR, 0.78; CI, 0.64–0.96; $P = .02$).¹¹⁷

There are several reports showing higher incidences of secondary malignancies when lenalidomide is used as a maintenance therapy post-transplantation or in a melphalan-containing regimen.^{118–121} In the FIRST trial, the overall incidence of secondary malignancies, including hematologic malignancies, was lower in the continuous lenalidomide/dexamethasone arm. The overall rates of second primary cancers were 3.0% in the continuous lenalidomide/dexamethasone arm, 6.0% in the arm receiving 18 cycles of lenalidomide/dexamethasone, and 5.0% in the MPT arm.¹¹⁷ In an analysis based on renal function of patients enrolled in the FIRST trial, continuous lenalidomide/low-dose dexamethasone compared with MPT reduced the risk of progression or death in patients with normal, mild, and moderate renal impairment by 33%, 30%, and 35%, respectively.¹²²

Lenalidomide/low-dose dexamethasone is considered a category 1, preferred option by the NCCN Multiple Myeloma Panel for transplant-ineligible patients with MM, especially the frail or elderly patients with standard-risk features. The panel recommends appropriate thromboprophylaxis for patients receiving this therapy. Based on the results of the FIRST trial,^{117,123} the NCCN Panel recommends considering treatment with continuous lenalidomide/dexamethasone until disease progression for patients who are not eligible for transplant.

Bortezomib/Cyclophosphamide/Dexamethasone

The role of bortezomib/cyclophosphamide/dexamethasone as initial therapy for patients with MM ineligible for SCT was studied in a small phase II trial ($n = 20$).¹²⁴ The median age of patients in this study was 76

years (range 66–90 years). After a median of 5 cycles, the ORR was 95% with 70% of patients achieving VGPR or better response. With respect to toxicity, 6 patients experienced non-hematologic grade 3/4 adverse events (20%), including muscle weakness, sepsis, and pneumonia. Neutropenia and thrombocytopenia were seen in 2 patients (10%).¹²⁴

Based on the above *and* the results from the EVOLUTION trial⁷⁹ (described earlier) that had included transplant-ineligible patients and the above phase II trial results,¹²⁴ the NCCN Panel has included bortezomib/cyclophosphamide/dexamethasone as a preferred option for non-transplant candidates. This is a preferred option, especially in patients with acute renal insufficiency. According to the NCCN Panel, one can consider switching to bortezomib/lenalidomide/dexamethasone after renal function improves.

Daratumumab/Bortezomib/Melphalan/Prednisone

In the randomized phase III trial (ALCYONE), randomized patients ($n = 706$) with newly diagnosed MM ineligible for transplant were to receive bortezomib/melphalan/prednisone with or without daratumumab until disease progression.¹²⁵ The addition of daratumumab increased the ORR (90.9% vs. 73.9%) and PFS at 18 months was 72% versus 50%. With respect to toxicity, there was an increased rate of grade 3 or 4 infections (23% vs. 15%) and daratumumab-related infusion reactions were seen in 27.7% of patients.

Based on the results of the ALCYCLONE trial, the NCCN Panel has included daratumumab/bortezomib/melphalan/prednisone as a category 1 option for treatment of patients with newly diagnosed MM not eligible for SCT.

**Other Recommended Primary Therapy Regimens for Non-Transplant Candidates*****Carfilzomib/Lenalidomide/Dexamethasone***

The results of a phase I/II trial demonstrated that the combination of carfilzomib/lenalidomide/dexamethasone is well-tolerated and is also effective in all newly diagnosed patients.⁸⁹ An updated follow-up analysis of the subset of 23 elderly patients (aged ≥65 years) showed that use of the carfilzomib, lenalidomide, and low-dose dexamethasone regimen for an extended period of time resulted in deep and durable responses. All patients achieved at least a PR and with a median follow-up of 30.5 months. PFS rate reported was 79.6% (95% CI, 53.5–92.0) and OS was 100%.⁹⁴

The phase II trial by Korde et al⁹⁷ also showed that treatment with the carfilzomib/lenalidomide/dexamethasone regimen results in high rates of deep remission. The results were very similar across age groups, with the oldest patient on the trial being 88 years of age,⁹⁷ and the regimen was found to be effective in individuals with high-risk disease.¹²⁶

Based on the above phase II studies that did not exclude transplant-ineligible patients, the NCCN Panel has included carfilzomib/lenalidomide/dexamethasone as an option for treatment of all patients with newly diagnosed MM, including those who are not eligible for SCT.

Carfilzomib/Cyclophosphamide/Dexamethasone

A phase II study examined the safety and efficacy of carfilzomib/cyclophosphamide/dexamethasone in patients ≥65 years of age with newly diagnosed MM and ineligible for autologous SCT.¹²⁷ Out of 55 patients, 52 (95%) had at least a PR, 39 of 55 (71%) patients had at least a VGPR, 27 of 55 (49%) patients had a near CR or CR, and 11 of 55

(20%) patients had an sCR. After a median follow-up of 18 months, the 2-year PFS and OS rates were 76% and 87%, respectively.¹²⁷ Frequently reported grade 3 to 5 toxicities were neutropenia (20%), anemia (11%), and cardiopulmonary events (7%). Peripheral neuropathy was limited to grades 1 and 2 (9%).

The NCCN Panel has included carfilzomib/cyclophosphamide/dexamethasone as an option for treatment of patients with newly diagnosed MM not eligible for SCT.

Ixazomib/Lenalidomide/Dexamethasone

A phase I/II study (discussed in the previous section for SCT-eligible candidates) evaluated the safety and efficacy of the all-oral combination of ixazomib with lenalidomide and dexamethasone in patients with newly diagnosed MM treated with combination lenalidomide and dexamethasone.⁹³ Both tolerability and activity of this regimen in older patients (those ≥65 years of age) was similar to that in younger patients in this study.

Based on the above phase II study, the NCCN Panel has included ixazomib in combination with lenalidomide and dexamethasone as a primary treatment option for all patients with newly diagnosed MM, including those *not* eligible for SCT.

Regimens Useful Under Certain Circumstances for Non-Transplant Candidates***Bortezomib/Dexamethasone***

A U.S. community-based, randomized, open-label, multicenter, phase IIIb UPFRONT trial compared safety and efficacy of 3 highly active bortezomib-based regimens in previously untreated elderly patients with MM ineligible for SCT.¹²⁸ The patients with symptomatic, measurable MM were randomized (1:1:1) to one of the following regimens:



bortezomib/dexamethasone (n = 168);
bortezomib/thalidomide/dexamethasone (n = 167); or
melphalan/prednisone/bortezomib (n = 167) followed by maintenance
therapy with bortezomib. The primary endpoint was PFS; secondary
endpoints included ORR, CR/near CR and VGPR rates, OS, and safety.
All 3 induction regimens exhibited substantial activity, with an ORR of 73%
(bortezomib/dexamethasone), 80%
(bortezomib/thalidomide/dexamethasone), and 70%
(melphalan/prednisone/bortezomib) during the treatment period.¹²⁹ After a
median follow-up of 42.7 months, the median PFS and OS were not
significantly different between the 3 treatment arms.¹²⁸ Response rates,
including CR and ≥VGPR, improved after bortezomib maintenance, with
no concomitant increase in the incidence of peripheral neuropathy.

While the triple regimen with bortezomib/lenalidomide/dexamethasone is
the preferred therapy for patients with newly diagnosed MM, elderly or frail
patients may be treated with doublet regimens. The NCCN Multiple
Myeloma Panel has included bortezomib/dexamethasone as a primary
therapy as an option that is useful under certain circumstances for patients
with MM who are ineligible for SCT.

Response Criteria

Assessing the response to treatment is a key determinant of myeloma
treatment.

The updated IMWG response criteria definitions^{9,130,131} for CR, sCR,
immunophenotypic CR, molecular CR, VGPR, PR, minimal response (MR)
for relapsed/refractory myeloma, stable disease (SD), and PD are outlined
in *Response Criteria for Multiple Myeloma* in the algorithm. This has been
recently updated to include measures of minimal residual disease (MRD)

assessments. It is recommended that the IMWG uniform response criteria
should be used in all clinical trials.¹³²

Monitoring After Primary Myeloma Therapy of Both Transplant and Non-Transplant Candidates

Patients on treatment should be monitored for response to therapy and for
symptoms related to disease and/or treatment. It is recommended to
re-evaluate (after 1–2 cycles) with the laboratory tests for M-protein (with
imaging and bone marrow examination if indicated) to determine treatment
response or whether the primary disease is progressive. Potential
transplant candidates should undergo a stem cell harvest after 4 to 6
cycles of therapy, collecting enough stem cells for two transplants
(depending on the intended number of transplants and age) in anticipation
of a tandem transplant or a second transplant as subsequent therapy.
Alternatively, all patients may consider continuation of primary therapy
until the best response is reached. The optimal duration of primary therapy
after achieving maximal response is unknown; hence, maintenance
therapy (see section on *Maintenance Therapy*) or observation can be
considered beyond maximal response.

Consider using the same imaging modality used during the initial workup
for the follow-up assessments. Follow-up tests after primary myeloma
therapy include those used for initial diagnosis: a CBC with differential and
platelet counts; serum creatinine and corrected serum calcium; and
quantification of M-protein and immunoglobulins. The serum FLC may be
assessed as clinically indicated (especially in patients with oligo- or non-
secretory MM). According to the NCCN Panel, response should be
assessed using the IMWG criteria.⁹

Other tests such as skeletal survey, whole body low-dose CT, bone
marrow aspiration and biopsy, skeletal MRI, and whole body FDG PET/CT



scan may be performed as indicated by symptoms to detect disease progression.

Transplant Eligibility

All patients are assessed to determine eligibility for SCT. The NCCN Panel recommends that all patients eligible for SCT should be referred for evaluation by SCT center and stem cells (for at least 2 transplants) should be harvested.

Stem Cell Transplants

High-dose therapy with stem cell support is a critical component in the treatment plan of eligible patients newly diagnosed with MM. The types of SCT may be single autologous SCT, a tandem SCT (a planned second course of high-dose therapy and SCT within 6 months of the first course), or an allogeneic SCT. An allogeneic SCT can be performed after prior myeloablative therapy or after nonmyeloablative therapy.

Nonmyeloablative therapy, also referred to as “mini transplant,” has been investigated as a technique to decrease toxicity of the allotransplant while preserving the alloimmune graft-versus-myeloma effect.^{133,134} It is important to note that nonmyeloablative allogeneic transplant by itself is not adequate therapy and is usually done following maximal tumor control through adequate induction therapy or an autologous SCT. An allogeneic SCT may also follow an autologous SCT.

The NCCN Guidelines for Multiple Myeloma indicate that all types of SCT are appropriate in different clinical settings; these indications are discussed further below. In general, all candidates for high-dose chemotherapy must have sufficient liver, renal, pulmonary, and cardiac function. However, renal dysfunction is not an absolute contraindication to transplant. Earlier studies of autologous transplant included total body irradiation (TBI) as a component of the preparative regimen. Regimens with chemotherapy have been shown to have equivalent efficacy and less

toxicity than TBI. TBI regimens have now been abandoned,¹³⁵ but newer, potentially less toxic radiation techniques aimed to deliver total marrow irradiation while reducing toxicities to non-target organs are currently undergoing evaluation in clinical trials.¹³⁶

Autologous Stem Cell Transplants

Autologous SCT results in high response rates and remains the standard of care after primary therapy for eligible patients. In 1996, results of the first randomized trial were reported; this trial demonstrated that autologous SCT is associated with statistically significantly higher response rates and increased OS and EFS when compared with the response of similar patients treated with conventional therapy.¹³⁷ In 2003, results of a second trial comparing high-dose therapy to standard therapy showed an increase in the CR rate and an improvement in OS (54 months in the high-dose group compared to 42 months for standard therapy).¹³⁸ Barlogie and colleagues reported on the results of an American trial that randomized 510 patients to receive high-dose therapy with autologous stem cell support or standard therapy.¹³⁹ With a median follow-up of 76 months, there were no differences in response rates, PFS, or OS between the two groups. The reason for the discrepant results are not clear, but may be related to differences in the specific high-dose and conventional regimens between the American and French study. For example, the American study included TBI as part of the high-dose regimen; TBI has subsequently been found to be inferior to high-dose melphalan.¹³⁵

Another trial included 190 patients 55 to 65 years of age randomized to standard or high-dose therapy.¹⁴⁰ This study was specifically designed to include older patients, since the median age of the participants in other trials ranged from 54 to 57 years and the median age in this trial was 61



years. After 120 months of follow-up, there was no significant difference in OS, although there was a trend toward improved EFS in the high-dose group ($P = .7$). Additionally, the period of time without symptoms, treatment, or treatment toxicity was significantly longer in the high-dose group. The study concluded that the equivalent survival suggests that the treatment choice between high-dose and conventional-dose chemotherapy should be based on personal choice in older patients. For example, an early transplant may be favored because patients can enjoy a longer interval of symptom-free time.

The choice of early versus late transplant was examined in a randomized French trial, and the results in both arms are comparable with respect to OS.¹⁴¹ However, early SCT was superior in terms of quality of life, assessed as time without symptoms and side effects from therapy.¹⁴¹ However, these early randomized studies of autologous SCT after primary therapy were designed and implemented before the availability of newer drugs.

A phase III study compared high-dose melphalan followed by autologous SCT with MPR (melphalan, prednisone, and lenalidomide) consolidation after induction. Patients ($n = 402$) were randomly assigned (in a 1:1:1:1 ratio) to one of the four groups: high-dose therapy and autologous SCT followed by maintenance with lenalidomide; high-dose therapy and SCT alone; primary therapy with MPR followed by lenalidomide; and primary therapy with lenalidomide alone.¹⁴² At a median follow-up of 51 months, SCT resulted in longer median PFS (43 vs. 22 months; HR 0.44; 95% CI, 0.32–0.61) and OS (82% vs. 65% at four years; HR 0.55; 95% CI, 0.32–0.93).¹⁴²

Results from the IFM 2005/01 study of patients with symptomatic myeloma receiving primary therapy with bortezomib and dexamethasone versus

VAD showed a marked improvement in ORR with bortezomib and dexamethasone over VAD (see *Preferred Primary Therapy Regimens for Transplant Candidates*).⁹⁵ Responses were evaluated after primary treatment and post-autologous SCT. After the first autologous SCT, CR/near-CR rates were 35.0% in the bortezomib plus dexamethasone arm, compared with 18.4% in the VAD arm.⁹⁵ The VGPR rates were 54.3% versus 37.2%. Median PFS was 36.0 months versus 29.7 months ($P = .064$) with bortezomib plus dexamethasone versus VAD after a median follow-up of 32.2 months.⁹⁵ Also, PFS was also significantly longer in the patients achieving greater than or equal to a VGPR after primary treatment than in patients achieving a less than VGPR (median 36 vs. 29.7 months).⁹⁵

In another study, 474 patients were randomized to primary therapy with bortezomib/dexamethasone/thalidomide ($n = 236$) or thalidomide/dexamethasone ($n = 238$) before double autologous SCT and as consolidation therapy after SCT.¹⁴³ The 3-drug regimen yielded high response rates compared with the 2-drug regimen, with a CR rate of 19% (vs. 5%) and greater than or equal to a VGPR of 62% (vs. 31%). After SCT, improved incremental responses were still seen with bortezomib/dexamethasone/thalidomide compared with thalidomide plus dexamethasone.¹⁴³ The IFM 2009 phase III trial compared the efficacy and safety of bortezomib/lenalidomide/dexamethasone alone versus bortezomib/lenalidomide/dexamethasone plus autologous SCT for the treatment of newly diagnosed MM in patients 65 years or younger.¹⁴⁴ The reported CR rate was 48% in the group that received induction therapy alone versus 59% in the transplantation group ($P = .03$). No MRD was detected in 65% of the patients who received bortezomib/lenalidomide/dexamethasone alone versus no MRD in 79% of



the patients who received induction therapy plus autologous SCT ($P < .001$).¹⁴⁴ There was a clear improvement in PFS with SCT (50 months vs. 36 months). These results clearly show the benefit of autologous SCT, with higher rates of durable responses in those with no MRD after initial therapy.¹⁴⁴ Taken together, the studies suggest that improved responses with the primary regimen result in improved outcomes after transplantation even for patients receiving an IMiD and PI-based triplet regimen.

The OS of patients in the IFM 2009 phase III trial was high in both groups—the one that received autologous SCT and the one that did not.¹⁴⁴

Although autologous SCT improved PFS it did not improve OS, suggesting that delaying SCT is an option and is not associated with negative effects on OS. According to the NCCN Guidelines, for transplant-eligible patients autologous SCT is an option after primary induction therapy (category 1) and for treatment of progressive/refractory disease after primary treatment.

Tandem Stem Cell Transplants

Tandem SCT refers to a planned second course of high-dose therapy and SCT within 6 months of the first course. Planned tandem transplants have been studied in several randomized trials. The IFM94 trial reported by Attal et al randomized newly diagnosed patients with MM to single or tandem autologous transplants.¹⁴⁵ A total of 78% of patients assigned to the tandem transplant group received the second transplant at a median time of 2.5 months after the first. A variety of options for therapy of relapsed disease were provided. For example, relapsing patients in either group underwent either no therapy, additional conventional therapy, or another SCT. The probability of EFS for 7 years after the diagnosis was 10% in the single transplant group compared to 20% in the double transplant group. In a subset analysis, those patients who did not achieve a complete CR or VGPR within 3 months after the first transplant

appeared to benefit the most from a second transplant. The investigators of the IFM94 study have suggested that the improvement in projected survival associated with tandem transplant is related not to improved response rates, but to longer durations of response. Four other randomized trials have compared single versus tandem transplant.^{140,146–}

¹⁴⁸ None of these trials showed a significant improvement in OS. However, since the median follow-up in these trials ranged from 42 to 53 months, the lack of significant improvement is not surprising. The trial by Cavo et al¹⁴⁶ found that patients not in CR or near CR after the first transplant benefited the most from a second transplant. This confirms the observations of the IFM94 trial using non-TBI-based high-dose regimens. In both the French and Italian trials, the benefit of a second autologous SCT was seen in patients who do not achieve a CR or VGPR (>90% reduction in M-protein level) with the first procedure. These two studies were not adequately powered to evaluate the equivalence of one versus two transplants in patients achieving a CR or VGPR after the first transplantation.

A review of long-term outcomes of several trials of autologous transplantation by Barlogie et al found that tandem transplantations were superior to both single transplantations and standard therapies.¹⁴⁹ Also, post-relapse survival was longer when EFS was sustained for at least 3.5 years after tandem transplantation.^{149–150} A recently reported result of an intergroup, multicenter, phase III study (EMN02/HO95 MM trial) suggests that tandem autologous SCT for newly diagnosed MM appears to be superior in extending PFS compared with single autologous SCT after induction therapy with a bortezomib-based regimen.¹⁵¹ However, in a recently published study, patients were randomly assigned after initial SCT to receive a second SCT followed by lenalidomide maintenance; four cycles of bortezomib, lenalidomide, and dexamethasone followed by



lenalidomide maintenance; or lenalidomide maintenance alone.¹⁵² At 38 months, all three arms showed similar PFS and OS.

The NCCN Multiple Myeloma Panel recommends collecting enough stem cells for 2 transplants in *all* eligible patients. According to the NCCN Multiple Myeloma Panel, a tandem transplant with or without maintenance therapy can be considered for all patients who are candidates for SCT, and is an option for patients who do not achieve at least a VGPR after the first autologous SCT. The support for use of maintenance therapy after tandem transplant comes from the study by Palumbo et al¹⁴² (discussed in the previous section, page MS-22), which addressed the role of maintenance therapy with lenalidomide after autologous transplantation.¹⁴² Although associated with more frequent grade 3 or 4 neutropenia and infections, maintenance therapy with lenalidomide was found to significantly reduce risk of disease progression or death (HR, 0.47) after both single and tandem transplantation compared with no maintenance.¹⁴²

A second autologous SCT can be considered at the time of disease relapse. A retrospective case-matched control analysis was performed comparing patients who underwent a second autologous SCT to those treated with conventional chemotherapy for relapsed MM.¹⁵³ Similar to previously published smaller studies,¹⁵⁴⁻¹⁵⁶ this retrospective analysis demonstrated that a second autologous SCT is associated with superior relapse-associated mortality compared with conventional chemotherapy (68% vs. 78%), along with improved OS (32% vs. 22%) at 4 years. In this analysis, factors associated with improved OS and PFS included younger age (<55 years), beta-2 microglobulin <2.5 mg/L at diagnosis, a remission duration of >9 months, and a greater than PR to their first autologous SCT. This analysis indicates that a second autologous transplant, for relapsed or progressive MM, may be an option for carefully selected

patients. Some of these patients can achieve durable complete or partial remission.^{156,157}

A multicenter, randomized phase III trial compared treatment with high-dose melphalan plus second autologous SCT with cyclophosphamide in patients with relapsed MM who had received autologous SCT as primary treatment.¹⁵⁸ The patients included in the study were greater than 18 years of age and needed treatment for progressive or relapsed disease at least 18 months after a previous autologous SCT. All patients first received bortezomib/doxorubicin/dexamethasone induction therapy. Patients with adequately harvested stem cells then were randomized to high-dose melphalan plus second autologous SCT (n = 89) or oral cyclophosphamide (n = 85). The primary endpoint was time to disease progression.¹⁵⁸ After a median follow-up of 31 months, median time to progression in patients who underwent second autologous SCT after induction therapy was 19 months versus 11 months for those treated with cyclophosphamide (HR, 0.36; 95% CI, 0.25–0.53; *P* < .0001). Grade 3-4 neutropenia (76% vs. 13%) and thrombocytopenia (51% vs. 5%) were higher in the group that underwent autologous SCT versus cyclophosphamide.¹⁵⁸ Median OS in the SCT group was 67 months versus 52 months in the cyclophosphamide maintenance group.¹⁵⁹

According to the NCCN Multiple Myeloma Panel, repeat autologous SCT for relapsed disease may be considered either on or off clinical trial depending on the time interval between the preceding SCT and documented progression. Data from retrospective studies¹⁶⁰⁻¹⁶³ suggest 2 to 3 years as the minimum length of remission for consideration of second autologous SCT for relapsed disease.



Allogeneic Stem Cell Transplant

Allogeneic SCT includes either myeloablative or nonmyeloablative (ie, “mini” transplant) transplants. Allogeneic SCT has been investigated as an alternative to autologous SCT to avoid the contamination of reinfused autologous tumor cells, but also to take advantage of the beneficial graft-versus-tumor effect associated with allogeneic transplants. However, lack of a suitable donor and increased morbidity has limited this approach, particularly for the typical older MM population. Non-myeloablative transplants are designed to decrease the morbidity of the high-dose chemotherapy but preserve the beneficial graft-versus-tumor effect. Therefore, the principal difference between myeloablative and nonmyeloablative transplants relates to the chemotherapy regimen used. Specific preparatory regimens have not been a focus of the NCCN Guidelines, and therefore these guidelines do not make a distinction between these approaches.

Given the small candidate pool, it is not surprising that there have been no randomized clinical trials comparing myeloablative allogeneic to autologous SCT, but multiple case series have been published describing allogeneic SCT as an initial therapy or as therapy for relapsed/refractory MM. In a 1999 review, Kyle reported a mortality rate of 25% within 100 days and overall transplant-related mortality of approximately 40% and few patients were cured.¹⁶⁴ Other reviews have also reported increased morbidity without convincing proof of improved survival.^{165,166} However, there are intriguing data from the SWOG randomized trial of autologous transplant versus conventional chemotherapy.¹³⁹ The original trial had an ablative, allogeneic transplant group consisting of patients with HLA identical siblings. Thirty-six patients received allografts, and due to the high 6-month mortality of 45%, the allogeneic arm was closed. After 7 years of follow-up the OS of the conventional chemotherapy, autologous, and allogeneic arms were all identical at 39%. The autologous and

conventional chemotherapy arms do not demonstrate a plateau, whereas the allogeneic curve was flat at 39%. This suggests that a proportion of these patients are long-term survivors. Thus, there is ongoing interest in myeloablative allogeneic SCT, particularly given the lack of a significant cure rate for single or tandem autologous SCT.

The NCCN Guidelines consider myeloablative allogeneic SCT an accepted option, preferably in a clinical trial in: 1) patients whose disease responds to primary therapy; 2) patients with primary PD; or 3) patients with PD after an initial autologous SCT.

Another strategy that has been investigated is initial autologous SCT followed by a mini-allogeneic transplant. A prospective trial by Bruno et al¹⁶⁷ showed that, among patients (<65 years) with HLA-matched siblings who received an autograft-allograft regimen, CR rate after allografting was 55%, compared with 26% after double autograft in patients without HLA-matched siblings. Median OS was higher (80 vs. 54 months). In the prospective PETHEMA trial in patients who did not achieve at least near-CR with a first autologous SCT, there was no significant difference in OS after double autologous SCT versus autologous SCT followed by mini-allogeneic transplant. However, a trend toward a longer PFS was observed in the group treated with autologous SCT followed by mini-allogeneic transplant.¹⁶⁸ In contrast, the IFM trial (99-03) by Garban et al¹⁶⁹ and the BMT-CTN 0102 trial¹⁷⁰ reported no OS or PFS advantage with autologous transplant followed by allogeneic transplant in any subgroup, even after 10 years of follow-up.

In a prospective study of patients with previously untreated MM, patients were selected for treatment with autologous SCT followed by reduced-intensity conditioning allogeneic SCT or autologous SCT based on the availability of an HLA-identical sibling.¹⁷¹ The induction chemotherapy in



this study consisted of the chemotherapy that was standard at the time—the VAD or VAD-like regimen. After 60 months, the incidence of relapse/disease progression was 49% in the group treated with autologous SCT followed by reduced-intensity conditioning allogeneic SCT versus 78% in the autologous SCT group. At 60 months, the OS and CR rates were 65% and 51%, respectively, for patients treated with autologous SCT followed by reduced-intensity conditioning allogeneic SCT compared with 58% and 41% for those treated with autologous SCT. Based on these study results, patients who have an HLA-identical sibling may be considered candidates for reduced-intensity allogeneic SCT as part of their first-line treatment.

Mini-allogeneic transplants have also been investigated as therapy for relapsed/refractory disease by virtue of their graft-versus-myeloma effect. Responsive disease to prior transplantation and younger age are associated with better response and OS rates.¹⁷²⁻¹⁷⁵ In a case series report, 54 patients with previously treated relapsed disease or PD were treated with an autologous SCT followed by a mini-allogeneic transplant.¹⁷³

There was a 78% OS at a median 552 days after the mini-allogeneic transplant, with a 57% CR rate and an ORR of 83%. This study concluded that this approach reduced the acute toxicities of a myeloablative allogeneic SCT while preserving anti-tumor activity. The largest case series was reported by the EBMT.¹⁷⁴ In this heterogeneous population of 229 patients, the 3-year OS and PFS were 41% and 21%, respectively. Adverse OS was associated with chemoresistant disease and more than 1 prior transplant, whereas improved¹⁷⁶ OS was associated with graft-versus-host disease (GVHD), confirming the importance of a graft-versus-leukemia effect. This study concluded that mini-allogeneic transplantation is feasible, but heavily pretreated disease and patients with PD are unlikely to benefit.

Patients whose disease either does not respond to or relapses after allogeneic stem cell grafting may receive donor lymphocyte infusions to stimulate a beneficial graft-versus-myeloma effect¹⁷⁷⁻¹⁸⁴ or other myeloma therapies on or off a clinical trial.

Follow-Up After Stem Cell Transplantation

Follow-up tests after SCT are similar to those done after primary myeloma therapy (see page MS-20).

In addition, MRD assessment is increasingly being incorporated into post-treatment assessments. MRD has been identified as an important prognostic factor. A prospective study of patients with newly diagnosed MM evaluated MRD in bone marrow samples and showed that at a median follow-up of 57 months, MRD negativity after autologous SCT translated to significantly improved PFS and OS rates.¹⁸⁵ Similarly, in another study, MRD negativity after autologous SCT was predictive of favorable PFS and OS.¹⁸⁶

Similar results have also been reported in the allogeneic SCT setting where the presence of MRD after allogeneic SCT has been associated with a significantly adverse PFS and OS.¹⁷⁶ The NCCN Panel recommends assessing for MRD during follow-up as indicated.¹³²

Maintenance Therapy

Lenalidomide as Maintenance Therapy After Autologous SCT
Lenalidomide as maintenance therapy after autologous transplantation has been evaluated in two independent randomized phase III studies.^{118,119}

In the CALGB 100104 trial, patients were randomized to maintenance therapy with lenalidomide (n = 231) versus placebo (n = 229) after



autologous SCT.¹¹⁹ At a median follow-up of 34 months, 37% of the patients who received lenalidomide versus 58% who received placebo had disease progression or died. The median time to progression in the lenalidomide group was 46 months versus 27 months in the placebo group ($P < .001$). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and in 6 patients who received placebo (3%).¹¹⁹

Data from the international, randomized, double-blind phase III IFM 2005-02 trial ($n = 614$) show that patients treated with lenalidomide as consolidation therapy after an autologous SCT followed by lenalidomide as maintenance therapy had upgraded responses. Of the 614 patients enrolled in the trial, 307 were randomly assigned to lenalidomide maintenance therapy and 307 to placebo. Maintenance treatment was continued until the patient withdrew consent, the disease progressed, or unacceptable toxic effects occurred. The final analysis of the IFM 2005-02 trial was performed after a median follow-up of 30 months and 264 patients had disease progression (104 in the lenalidomide group and 160 in the placebo group). The median PFS was 41 months in the lenalidomide group, compared with 23 months in the placebo group (HR, 0.50; $P < .001$; median follow-up period was 30 months). The probability of surviving without progression for 3 years after randomization was 59% in those treated with lenalidomide and 35% in those who received the placebo. The benefit of lenalidomide maintenance therapy, evidenced by rate of PFS at 3 years after randomization, was higher in all patients who received lenalidomide maintenance therapy compared with those who received placebo. This benefit was observed in patients who had a VGPR at randomization (64% vs. 49%, $P = .006$) and those who did not (51% vs. 18%, $P < .001$).¹¹⁸ An increased incidence of second primary cancers was observed in the lenalidomide group (32 had second primary cancers in the lenalidomide group and 12 in the placebo group).¹¹⁸ The updated survival

analysis of the same study after 91 months for follow-up reported median time to progression of 57.3 months (95% CI, 44.2–73.3) with lenalidomide and 28.9 months (23.0–36.3) with placebo (HR, 0.57; 95% CI, 0.46–0.71; $P < .0001$).¹⁸⁷ The most common grade 3-4 adverse events in the lenalidomide group compared to placebo were neutropenia (50% vs. 18%) and thrombocytopenia (15% vs. 5%). An increased rate of second primary malignancies (hematologic plus solid tumor) were diagnosed in the lenalidomide group compared with placebo (14% vs. 4%).¹⁸⁷

The study by Palumbo et al¹⁴² (discussed in *Autologous Stem Cell Transplants*) showed that although maintenance therapy with lenalidomide is associated with more frequent grade 3 or 4 neutropenia and infections, it significantly reduced risk of disease progression or death (HR, 0.47) compared with no maintenance.¹⁴²

The benefit of lenalidomide maintenance was studied in a meta-analysis of data from 1209 patients enrolled in the trials discussed above randomized to maintenance with lenalidomide or placebo.¹⁸⁸ The study showed improved median PFS with lenalidomide maintenance (52.8 vs. 23.5 months; HR 0.48; 95% CI, 0.42–0.55). At 7 years, the OS was 62% in the group receiving lenalidomide maintenance versus 50% in those receiving placebo. In those with high-risk cytogenetics, a PFS benefit, but not an OS benefit was seen with lenalidomide maintenance versus placebo.

The lenalidomide group had higher rates of second primary malignancy occurring before progression, and the rates of PD were higher in the group receiving placebo.

Maintenance therapy after allogeneic transplant: A report from the HOVON 76 trial indicates that lenalidomide maintenance may not be a feasible option after mini-allogeneic SCT.¹⁸⁹ However, another recently



reported study has shown the feasibility of maintenance therapy with low-dose lenalidomide after allogeneic SCT in patients with high-risk MM.¹⁹⁰

Lenalidomide as Maintenance Therapy After Non-Transplant Primary Treatment

Data from the phase III MM-015 study show that lenalidomide maintenance after primary therapy with melphalan/prednisone/lenalidomide (MPL) significantly reduced the risk of disease progression and also increased PFS.¹⁹¹ In this study, newly diagnosed patients with MM (n = 459) aged ≥ 65 years were randomized to receive MP followed by placebo, MPL, or MPL followed by lenalidomide until progression. Maintenance with lenalidomide significantly prolonged PFS. The PFS of patients treated with MPL followed by maintenance lenalidomide was significantly prolonged (n = 152; median, 31 months) compared with the other two arms: MPL (n = 153; median, 14 months; HR, 0.49; $P < .001$) or MP (n = 154; median, 13 months; HR, 0.40; $P < .001$). Lenalidomide maintenance therapy improved PFS by 66% compared with placebo, regardless of age.¹⁹¹ In the FIRST trial, use of lenalidomide indefinitely until progression was associated with a superior PFS compared with a fixed duration of 18 months.

Based on the evidence from the phase III trials,^{118,119,191} the NCCN Multiple Myeloma Panel lists single-agent lenalidomide as one of the preferred maintenance regimens (category 1). Lenalidomide lacks the neurologic toxicity seen with thalidomide. However, there seems to be an increased risk for secondary cancers, especially post-transplantation,¹¹⁸⁻¹²⁰ or after a melphalan-containing regimen.¹²¹ According to the results of the FIRST trial, in the continuous lenalidomide/dexamethasone arm, the absence of the alkylator melphalan seems to be more effective in terms of improving PFS and lowering incidence of second malignancies.¹¹⁷

A meta-analysis of 4 randomized controlled trials examined patients treated with lenalidomide maintenance versus patients with no maintenance or placebo in both the transplant and non-transplant settings.¹⁹² The analysis showed that patients treated with lenalidomide maintenance had significantly improved PFS (HR, 0.49; $P < .001$) and a trend toward OS (HR, 0.77; $P = .071$) versus no maintenance or placebo.¹⁹³ There was significantly more grade 3/4 neutropenia with the use of lenalidomide and a 2-fold increased risk of secondary malignancies.

The benefits of improved PFS with lenalidomide maintenance must be weighed against the increased rate of severe (grade 3 and 4) neutropenia, risk of second cancers, and other toxicities.¹⁹⁴ The NCCN Panel notes that the benefits and risks of maintenance therapy with lenalidomide versus secondary cancers should be discussed with patients.

Other Recommended Maintenance Regimens

Bortezomib as Maintenance Therapy After Autologous SCT

The results from the HOVON study show that maintenance with single-agent bortezomib after autologous SCT is well tolerated and is associated with improvement of ORR.⁸⁶ Patients in the HOVON trial were randomly assigned to one of the two arms consisting of either primary treatment with VAD followed by autologous SCT and maintenance with thalidomide or with bortezomib/doxorubicin/dexamethasone followed by autologous SCT and bortezomib as maintenance therapy for 2 years. The study reported high near-CR/CR rates after primary treatment with the bortezomib-based regimen. Bortezomib as maintenance therapy was well tolerated and associated with additional improvement of response rates⁸⁶ (see *Preferred Primary Therapy Regimens for Transplant Candidates*).



A multicenter phase III trial in newly diagnosed patients with MM showed that consolidation with bortezomib after autologous SCT improved PFS only in patients not achieving at least VGPR after autologous SCT.¹⁹⁵ There was no difference in PFS in patients with ≥VGPR after autologous SCT.

Bortezomib as Maintenance Therapy After Non-Transplant Active Primary Treatment

The results of the phase III UPFRONT study also show that maintenance with single-agent bortezomib is well-tolerated when administered after treatment with bortezomib-based primary therapy.¹²⁸ Newly diagnosed patients with MM ineligible for high-dose therapy and SCT enrolled in the UPFRONT trial were randomized (1:1:1) and treated with one of the following bortezomib-based primary regimens: bortezomib and dexamethasone; bortezomib in combination with thalidomide and dexamethasone; or bortezomib with melphalan and prednisone followed by maintenance treatment with bortezomib. The results show that the response rates, including CR and ≥VGPR, improved after bortezomib maintenance in all arms, with no concomitant increase in the incidence of peripheral neuropathy.¹²⁸

The NCCN Multiple Myeloma Panel members have added bortezomib as a maintenance therapy option.

Treatment of Progressive or Relapsed Myeloma

Therapy for previously treated relapsed/refractory MM is considered in the following clinical situations: patients with relapsed disease after allogeneic or autologous SCT; patients with primary PD after initial autologous or allogeneic SCT; and patients ineligible for SCT with progressive or relapsing disease after initial primary therapy.

A variety of therapies are available as options for previously treated MM depending on the prior therapy and duration of response. The options include systemic therapy; SCT (for eligible patients who did not receive SCT as part of their initial treatment); or clinical trial. For those who had autologous SCT as part of initial treatment and had a durable response or had SD, consideration must be given to a second transplantation on or off clinical trial at the time of relapse/disease progression.

If the relapse occurs at greater than 6 months after completion of the initial primary therapy, patients may be retreated with the same primary regimen.

Preferred Regimens for Previously Treated Multiple Myeloma

Bortezomib/Lenalidomide/Dexamethasone

Data from preclinical studies showed lenalidomide sensitizes myeloma cells to bortezomib and dexamethasone. The results of phase I and phase II studies show that bortezomib/lenalidomide/dexamethasone is well tolerated and active, with durable responses in heavily pretreated patients with relapsed and/or refractory MM, including patients who have had prior lenalidomide, bortezomib, thalidomide, and SCT.^{196,197} After a median follow-up of 44 months, the median PFS was 9.5 months and median OS was 30 months (95% CI, 24–37).¹⁹⁷ The NCCN Multiple Myeloma Panel members have included bortezomib/lenalidomide/dexamethasone as a preferred option for relapsed/refractory MM.

Carfilzomib/Lenalidomide/Dexamethasone

A randomized, multicenter, phase III trial of 792 patients (ASPIRE) studied the combination of lenalidomide and dexamethasone with or without carfilzomib in patients with relapsed/refractory myeloma who had received one to three prior lines of therapy. The primary endpoint of the study was PFS. The results showed that addition of carfilzomib to lenalidomide and



dexamethasone significantly improved PFS by 8.7 months (26.3 months for the carfilzomib arm vs. 17.6 months for lenalidomide and low-dose dexamethasone; HR for progression or death, 0.69; 95% CI, 0.57–0.83; $P = .0001$). The median duration of treatment was longer in the carfilzomib group (88.0 weeks vs. 57 weeks). The incidence of peripheral neuropathy was nearly identical in both arms (17.1% in the carfilzomib group vs. 17.0%). Non-hematologic adverse effects (\geq grade 3) that were higher in the carfilzomib group compared with lenalidomide and dexamethasone included dyspnea (2.8% vs. 1.8%), cardiac failure (3.8% vs. 1.8%), and hypertension (4.3% and 1.8%). There were fewer discontinuations due to side effects in the carfilzomib arm (15.3% vs. 17.7%). Patients in the carfilzomib arm reported superior health-related quality of life than those who received lenalidomide and dexamethasone.¹⁹⁸

Based on the above data, the NCCN Multiple Myeloma Panel has included the combination of carfilzomib with lenalidomide and dexamethasone as a preferred option for patients with relapsed/refractory myeloma (category 1).

Carfilzomib (twice weekly)/Dexamethasone

The results of the phase III ENDEAVOR trial in patients with relapsed/refractory MM treated with multiple prior lines of therapy showed a 2-fold improvement in median PFS with carfilzomib/dexamethasone compared to bortezomib/dexamethasone (18.7 months vs. 9.4 months; HR, 0.53; $P < .0001$).¹⁹⁹ ORR was 77% in the carfilzomib group versus 63% in the bortezomib group; rates of CR or better were 13% and 6% and rates of VGPR were 42% and 22%, respectively. Median duration of response was 21.3 months in the carfilzomib group and 10.4 months in the bortezomib group. Adverse events (grade 3 or higher) in the carfilzomib arm compared to the bortezomib arm included hypertension (6% vs. 3%), anemia (12% vs. 9%), thrombocytopenia (10% vs. 14%), and dyspnea

(5% vs. 2%). Rate of grade ≥ 2 peripheral neuropathy was 6% in the carfilzomib group and 32% in the bortezomib group.¹⁹⁹

The OS analysis showed that those treated with carfilzomib/dexamethasone lived 7.6 months longer (median OS was 47.6 months in the carfilzomib group vs. 40 months in the bortezomib group; HR, 0.791 [95% CI, 0.648–0.964]; $P = .010$).²⁰⁰ The most frequent grade 3 or worse adverse events in the carfilzomib arm compared to the bortezomib arm included hypertension (15% vs. 3%), anemia (16% vs. 10%), dyspnea (6% vs. 2%), decreased lymphocyte count (6% vs. 2%), diarrhea (4% vs. 9%), and peripheral neuropathy (1% vs. 6%).²⁰⁰ Rates of thrombocytopenia, pneumonia, and fatigue were similar in both groups.²⁰⁰

Based on the above phase III data, the NCCN Multiple Myeloma Panel has included the combination of carfilzomib (twice weekly) and dexamethasone as a preferred option for patients with relapsed/refractory myeloma (category 1).

Carfilzomib (weekly)/Dexamethasone

The data from a phase 1 study (CHAMPION-1) determined the maximum tolerated dose of carfilzomib (in combination with dexamethasone) to be 70 mg/m², once weekly.²⁰¹ Subsequently, a phase II study was conducted in patients with relapsed/refractory MM ($n = 104$) to evaluate safety and efficacy of weekly dosing of carfilzomib with dexamethasone. The ORR observed in this study was 77% (95% CI, 68–85). At 13.6 months, the median PFS was 16.2 months (95% CI, 10.2–21.0).²⁰² The most common grade 3 or higher adverse events occurring in at least 3% of all patients were fatigue (11%), pneumonia (6%), acute kidney injury (7%), and hypertension (8%).



The NCCN Multiple Myeloma Panel has included the carfilzomib (weekly)/dexamethasone regimen as an option for patients with relapsed/refractory myeloma.

Daratumumab/Bortezomib/Dexamethasone

A phase III trial showed that adding daratumumab to bortezomib and dexamethasone markedly improved outcomes for patients with recurrent/refractory MM.²⁰³ Patients (n = 498) were randomized to receive daratumumab/bortezomib/dexamethasone or bortezomib/dexamethasone. The ORR in the daratumumab arm was 82.9% compared to 63.2% in the control arm ($P < .001$).²⁰³ The rates of VGPR and CR were double in the daratumumab arm compared to the control arm (59.2% vs. 29.1%, $P < .001$ and 19.2% vs. 9.0%, $P = .001$, respectively). The 12-month estimated rate of PFS was significantly higher in the daratumumab arm compared to the control arm (60.7% vs. 26.9%).²⁰³ The most common grade 3 or 4 adverse events reported in the daratumumab and control groups were thrombocytopenia (45.3% and 32.9%, respectively), anemia (14.4% and 16.0%, respectively), and neutropenia (12.8% and 4.2%, respectively).²⁰³ Grade 1 or 2 infusion-related reactions associated with daratumumab were reported in 45.3% of the patients in the daratumumab group and grade 3 in 8.6% of the patients. These infusion-related reaction rates are consistent with findings from previous trials of daratumumab.^{204,205}

Based on the above phase III data, the NCCN Panel has added daratumumab/bortezomib/dexamethasone as a preferred option (category 1) for the treatment of patients with relapsed/refractory MM.

Daratumumab/Lenalidomide/Dexamethasone

A phase III trial randomized patients (n = 569) 1:1 to receive daratumumab/lenalidomide/dexamethasone or lenalidomide/dexamethasone.²⁰⁶

According to the reported results, the ORR (in patients with an evaluable response) was higher in the daratumumab group (92.9% vs. 76.4%; $P < .001$) as was the CR (43.1% vs. 19.2%, $P < .001$). In the group that received daratumumab, the estimated rate of PFS at 12 months was 83.2% (95% CI, 78.3–87.2) compared with 60.1% (95% CI, 54.0–65.7) in the lenalidomide/dexamethasone group. Since deeper responses are known to result in longer PFS, a subgroup analysis showed that in those having a PR or better, the rate of PFS at 12 months was 87.8% (95% CI, 83.1–91.3) with daratumumab versus 73.6% (95% CI, 67.0–79.1) with lenalidomide/dexamethasone. Among patients with a VGPR or better, the rate of PFS was further improved: 91.7% (95% CI, 87.1–94.8) in the daratumumab group versus 85.8% (95% CI, 78.1–90.9) in the lenalidomide/dexamethasone group. The estimated rate of OS at 12 months in the daratumumab group was also significantly higher: 92.1% (95% CI, 88.2–94.7) compared with 86.8% (95% CI, 82.2–90.3) in the lenalidomide/dexamethasone group.

The most common adverse events of grade 3 or 4 in patients treated with the daratumumab regimen versus lenalidomide/dexamethasone were neutropenia (51.9 vs. 37.0%), thrombocytopenia (12.7% vs. 13.5%), and anemia (12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions (mostly grade 1 or 2) were reported in 47.7% of the patients.

Based on the above phase III data, the NCCN Panel has added daratumumab/lenalidomide/dexamethasone as a preferred option (category 1) for the treatment of patients with relapsed/refractory MM.

*Elotuzumab/Lenalidomide/Dexamethasone*

Elotuzumab is a humanized monoclonal antibody targeted against signaling lymphocytic activation molecule F7 (SLAMF7). SLAMF7, also called CS1 (cell-surface glycoprotein CD2 subset 1) is a glycoprotein expressed on myeloma and natural killer cells but not on normal tissues.²⁰⁷ The FDA has approved elotuzumab in combination with lenalidomide and dexamethasone for the treatment of patients with MM who have received one to three prior therapies. This is based on the results of the phase III trial, ELOQUENT-2. The trial randomized 646 patients (1:1) to receive either elotuzumab in combination with lenalidomide and dexamethasone or lenalidomide and dexamethasone alone.²⁰⁸

The rates of PFS at the end of 1 and 2 years were higher for those receiving the elotuzumab-containing regimen (68% at 1 year and 41% at 2 years) compared with those receiving lenalidomide and dexamethasone alone (57% at 1 year and 27% at 2 years).²⁰⁸ Median PFS in the group receiving the elotuzumab-containing regimen was 19.4 months versus 14.9 months in those receiving lenalidomide and dexamethasone alone (HR for progression or death in the elotuzumab group, 0.70; 95% CI, 0.57–0.85; $P < .001$) indicating a relative reduction of 30% in the risk of disease progression or death.²⁰⁸ Common grade 3 or 4 adverse events in both arms of the trial were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients.²⁰⁸

Consistent with the above findings, a subset analysis of 3-year follow-up reported a reduced risk of progression by 27% with elotuzumab/lenalidomide/dexamethasone combination compared with lenalidomide/dexamethasone.²⁰⁹

Based on the above data and FDA approval the NCCN Panel has included elotuzumab in combination with lenalidomide and dexamethasone as a preferred regimen option (category 1) for previously treated MM.

Ixazomib/Lenalidomide/Dexamethasone

A double-blind, randomized, placebo-controlled, phase III TOURMALINE MM1 trial randomized 722 patients with relapsed and/or refractory MM to a combination of ixazomib plus lenalidomide and dexamethasone or lenalidomide and dexamethasone alone (control group). This trial was designed based on the promising results of a phase I/II study (discussed under *Other Recommended Primary Therapy Regimens for Transplant Candidates*).⁹³

The results of the TOURMALINE MM1 trial show a significant improvement in PFS with the ixazomib-containing regimen. After a median follow-up of almost 15 months, a 35% improvement in PFS was seen in the group treated with the ixazomib regimen compared with the control group (HR, 0.74; $P = .01$).²¹⁰ Median PFS was 20.6 months in the ixazomib-treated group versus 14.7 months in the group receiving lenalidomide and dexamethasone alone. In the ixazomib-treated group versus the control group, the ORR (78% vs. 72%, $P = .035$) and CR (11.7% vs. 6.6%, $P = .019$) were also improved. Of note, patients with high-risk cytogenetics enrolled in the trial receiving ixazomib had a similar HR for PFS as the entire study population (HR, 0.596 and 0.543, respectively).²¹⁰ Grade ≥ 3 adverse events were reported in 74% and 69% of patients in the ixazomib-treated and control groups, respectively. These included anemia (9% with ixazomib/lenalidomide/dexamethasone vs. 13% with lenalidomide/dexamethasone), thrombocytopenia (19% vs. 9%), and neutropenia (23% vs. 24%).²¹⁰ The addition of the ixazomib/lenalidomide/dexamethasone group had a slightly higher rate of



peripheral neuropathy compared to lenalidomide/dexamethasone (27% vs. 22%).

Based on the results of the phase III TOURMALINE MM1 trial²⁷⁰ the NCCN Panel has included ixazomib/lenalidomide/dexamethasone as a preferred regimen option for previously treated MM.

Other Recommended Regimens for Previously Treated MM

Bendamustine/Lenalidomide/Dexamethasone

A multicenter phase I/II trial investigated the combination of bendamustine, lenalidomide, and dexamethasone as treatment for patients (n = 29) with relapsed/refractory MM.²⁷⁷ PR rate was seen in 52% (n = 13) of patients, with VGPR in 24% (n = 6) of patients. The median PFS in the trial was 6.1 months (95% CI, 3.7–9.4 months), and the one-year PFS rate was 20% (95% CI, 6%–41%).²⁷⁷ The NCCN Panel has included lenalidomide in combination with bendamustine and dexamethasone as a treatment option for relapsed/refractory MM.

Bendamustine/Bortezomib/Dexamethasone

A phase II study evaluated bendamustine/bortezomib/dexamethasone administered over six 28-day cycles and then every 56 days for six more cycles in patients (n = 75; median age 68 years) with relapsed/refractory MM treated with multiple prior therapies and *not* refractory to bortezomib. The PR rate was 71.5% (16% CR, 18.5% VGPR, 37% partial remission). At 12-month follow-up, median time to progression was 16.5 months and 1-year OS was 78%.²⁷²

Bortezomib/Liposomal Doxorubicin/Dexamethasone

Bortezomib with liposomal doxorubicin (PLD) was approved by the FDA as a treatment option for patients with MM who have not previously received

bortezomib and have received at least one prior therapy. The approval was based on a priority review of data from an international phase III trial (n = 646) showing that use of the combination significantly extended the median time to disease progression compared with bortezomib alone (9.3 vs. 6.5 months).²⁷³ Median duration of response was increased from 7.0 months to 10.2 months with the combination therapy. Based on these results, the NCCN Multiple Myeloma Panel considers bortezomib with the PLD regimen as a category 1 option for patients with relapsed/refractory MM.

Bortezomib/Cyclophosphamide/Dexamethasone

The effects of adding of an alkylating agent (such as cyclophosphamide) and a novel agent (such as lenalidomide or bortezomib) to dexamethasone have been investigated for patients with relapsed/refractory MM. The combination of bortezomib, dexamethasone, and cyclophosphamide was found to be effective in patients with relapsed/refractory myeloma with an acceptable toxicity profile.^{274,275} The NCCN Multiple Myeloma Panel members have included bortezomib/cyclophosphamide/dexamethasone to the list of options for relapsed/refractory MM.

Bortezomib/Dexamethasone

Addition of dexamethasone to bortezomib in patients with relapsed/refractory myeloma who had PD during bortezomib monotherapy resulted in improvement of response in 18% to 34% of patients.²⁷⁶⁻²⁷⁸ The NCCN Multiple Myeloma Panel members have included the bortezomib and dexamethasone regimen as an option for patients with relapsed/refractory myeloma (category 1).

*Carfilzomib/Cyclophosphamide/Dexamethasone*

A phase II trial compared the safety and toxicity of carfilzomib/cyclophosphamide/dexamethasone with bortezomib/cyclophosphamide/dexamethasone in patients who had received one prior regimen for relapsed/refractory MM.²¹⁹ The study reported carfilzomib/cyclophosphamide/dexamethasone as well tolerated with toxicity profile of carfilzomib being similar to that seen in other trials.²¹⁹ This regimen is included in the NCCN Guidelines for Multiple Myeloma as an option for patients with relapsed/refractory myeloma.

Lenalidomide/Dexamethasone

Lenalidomide combined with dexamethasone received approval from the FDA as a treatment option for patients with MM who had received at least one prior treatment. This was based on the results of two studies of a total of 692 patients randomized to receive dexamethasone either with or without lenalidomide. The primary efficacy endpoint in both studies was time to progression. A pre-planned interim analysis of both studies reported that the median time to progression was significantly longer in the lenalidomide arm compared to the control group.^{220,221} The updated clinical data from the pivotal North American phase III trial (MM-009) in 353 previously treated patients with MM reported increased OS and median time to disease progression in patients receiving lenalidomide plus dexamethasone compared to patients receiving dexamethasone plus placebo.²²¹ Similar results were seen in the international trial MM-010.²²⁰ Patients in both of these trials had been heavily treated before enrollment. Many had 3 or more prior lines of therapies with other agents and more than 50% of patients having undergone SCT.^{220,221} Most adverse events and grade 3/4 adverse events were more frequent in patients with MM who received the combination of lenalidomide/dexamethasone compared to placebo and dexamethasone. Thrombocytopenia (61.5%) and

neutropenia (58.8%) were the most frequently reported adverse events observed. The NCCN Multiple Myeloma Panel now considers this regimen as a category 1 option as therapy for patients with relapsed/refractory MM. Lenalidomide monotherapy has also been investigated and found effective in patients with relapsed/refractory MM.²²² The NCCN Multiple Myeloma Panel suggests considering lenalidomide monotherapy for steroid-intolerant individuals.

Lenalidomide/Cyclophosphamide/Dexamethasone

A retrospective analysis to assess the efficacy of lenalidomide in combination with cyclophosphamide and dexamethasone showed that this regimen is effective in heavily pre-treated patients with manageable adverse effects.²²³

Pomalidomide/Dexamethasone

Pomalidomide, like lenalidomide, is an analogue of thalidomide. It possesses potent immunomodulatory and significant anti-myeloma properties.²²⁴

A phase III, multicenter, randomized, open-label study (MM-003) conducted in Europe compared the efficacy and safety of pomalidomide and low-dose dexamethasone (n = 302) versus high-dose dexamethasone (n = 153) in patients with relapsed MM who were refractory to both lenalidomide and bortezomib.²²⁵ After a median follow-up of 10 months, PFS, the primary endpoint of the study, was significantly longer in patients who received pomalidomide and low-dose dexamethasone compared with those who received high-dose dexamethasone (4.0 vs. 1.9 months; HR, 0.45; $P < .0001$).²²⁵ The median OS was significantly longer in the patients who received pomalidomide and low-dose dexamethasone as well (12.7 months vs. 8.1 months; HR, 0.74; $P = .0285$).²²⁵ The most common



hematologic grade 3 and 4 adverse effects found to be higher with the low-dose dexamethasone compared with the high-dose dexamethasone were neutropenia and pneumonia.²²⁵ Other phase III studies of pomalidomide plus low-dose dexamethasone in combination with other agents (eg, bortezomib) are currently ongoing (Clinical Trial ID: NCT01734928). A European multicenter, single-arm, open-label, phase IIIb trial evaluated the safety and efficacy of pomalidomide and low-dose dexamethasone in a large patient population (N = 604).²²⁶ The median PFS reported was 4.2 months and OS was 11.9 months. Whether the patients received prior lenalidomide or bortezomib, the PFS, OS, and ORR reported were similar.²²⁶ The results of this trial are consistent with those observed in the pivotal MM-003 trial.²²⁵

In addition, several complementary phase II studies have been published evaluating the use of pomalidomide and dexamethasone in patients with MM relapsed/refractory to lenalidomide and/or bortezomib. A phase II study investigated two different dose regimens of pomalidomide and dexamethasone in 84 patients with advanced MM. Pomalidomide (4 mg) was given orally on days 1 to 21 or continuously over a 28-day cycle, and dexamethasone (40 mg) was given orally once weekly.²²⁷ ORR was 35% and 34% for patients in the 21-day and 28-day groups, respectively. With median follow-up of 23 months, median duration of response, PFS, and OS were 7.3, 4.6, and 14.9 months across both groups, respectively. All patients experienced similar adverse events in both groups. The adverse events were primarily due to myelosuppression.²²⁷ Another phase II trial evaluated two doses of pomalidomide 2 or 4 mg/day with dexamethasone 40 mg weekly in heavily pre-treated patients (n = 35).²²⁸ The ORR in the 2-mg cohort was 49% versus 43% in the 4-mg cohort. OS at 6 months

was 78% and 67% in the 2- and 4-mg cohort, respectively.

Myelosuppression was the most common toxicity.²²⁸

The FDA has approved pomalidomide for patients with MM who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. The FDA-recommended dose and schedule of pomalidomide is 4 mg orally on days 1 to 21 of repeated 28-day cycles with cycles repeated until disease progression along with the recommendation to monitor patients for hematologic toxicities, especially neutropenia.

Based on the above data, the NCCN Panel has included pomalidomide plus dexamethasone as a therapeutic option in patients who have received at least two prior therapies, including an IMiD and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy (category 1). For steroid-intolerant individuals, the NCCN Multiple Myeloma Panel suggests considering pomalidomide monotherapy.

Pomalidomide/Bortezomib/Dexamethasone

A phase 3 trial studied pomalidomide/bortezomib/dexamethasone versus bortezomib/dexamethasone in patients (n= 559) with relapsed or refractory multiple myeloma who previously received lenalidomide.²²⁹ After a median follow-up of 15.9 months, a significantly improved PFS was seen in the pomalidomide arm (median 11.20 months vs. 7.10 months; HR, 0.61; 95% CI, 0.49–0.77; $P < .0001$). The most common grade 3/4 treatment-related adverse events in the pomalidomide arm reported in this trial were neutropenia, infections, and thrombocytopenia.²²⁹



The NCCN Panel has included pomalidomide/bortezomib/dexamethasone as a therapeutic option in patients who have received at least two prior therapies, including an IMiD and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Pomalidomide/Carfilzomib/Dexamethasone

Based on the encouraging results of the phase I study,²³⁰ a phase II study was carried out to evaluate the safety and efficacy of pomalidomide, carfilzomib, and dexamethasone in lenalidomide-refractory and proteasome-naïve/sensitive patients with relapsed/refractory MM. After a median of 7.2 cycles (range = 0.6–27.1 cycles), PR was 84%, MR was 91%, VGPR was 26%, and CR/near CR was 12%.²³¹ After a median follow-up of 18 months (range = 1–39 months), the median PFS for all 55 patients was 12.9 months and the estimated 18-month OS was 86.5%.²³⁷

The NCCN Panel has included this regimen pomalidomide/carfilzomib/dexamethasone as a therapeutic option in patients who have received at least two prior therapies, including an IMiD and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Pomalidomide/Cyclophosphamide/Dexamethasone

A phase II study compared the combination of pomalidomide/cyclophosphamide/dexamethasone to pomalidomide/dexamethasone in patients (n = 70) with relapsed/refractory MM who had received more than 2 prior therapies.²³²

The triple-drug combination significantly improved the ORR (≥PR, 64.7% vs. 38.9%; *P* = .0355). The median PFS reported was 9.5 months versus 4.4 months. There were no significant differences in adverse event reports between the treatment arms; grade 3 and 4 anemia, neutropenia, and

thrombocytopenia, respectively, were reported in 11%, 31%, and 6% of patients treated with pomalidomide/dexamethasone and 24%, 52%, and 15% of patients treated with the triplet regimen.²³² Similar results were reported by a single-center retrospective study²³³ of patients (n = 20) with relapsed/refractory MM who received pomalidomide/cyclophosphamide/dexamethasone until transplant or disease progression was reported.²³² Response to the triple-drug regimen was 63%, with nearly half of patients (42%) responding after 1 cycle with a median time to response of 3 cycles. One-year median PFS was 80.7% and 65% of patients were relapse-free.²³³

Based on the above phase II trial data, the NCCN Panel has included pomalidomide/cyclophosphamide/dexamethasone as a treatment option for patients with relapsed/refractory MM who have received at least one prior therapy.

Daratumumab

Daratumumab is a human IgG kappa monoclonal antibody that targets the CD38 surface protein on myeloma cells.²⁰⁴ In a phase I/II study, patients who had received more than 3 lines of therapy including an IMiD and a PI or were double refractory to PI and IMiD were randomized to 2 different doses of daratumumab (8 mg/kg vs. 16 mg/kg). ORR was 29.2% (3 sCR, 10 VGPR, and 18 PR). Median duration of response was 7.4 months and median time to progression was 3.7 months. The estimated 1-year OS rate was 65%.²⁰⁵ Adverse events reported were fatigue (39.6%), anemia (33.0%), nausea (29.2%), and thrombocytopenia (25.5%). Grade 1 and 2 infusion-related reactions were seen in 42.5% of patients, mainly during first infusion. No patients discontinued the study due to infusion-related reactions.²⁰⁵



Based on the above phase II results and FDA approval, the panel has added daratumumab as an option for the treatment of patients with MM who have received at least 3 prior lines of therapy including a PI and an IMiD or who are double refractory to a PI and IMiD.

Daratumumab/Pomalidomide/Dexamethasone

The combination of daratumumab/pomalidomide/dexamethasone was evaluated in an open-label, multicenter, phase 1b study (MMY1001). This study included patients (n = 103 patients) who had received at least two prior lines of therapy (excluding daratumumab or pomalidomide).²³⁴ At a median follow-up of 13.1 months, the ORR was 60%. The median PFS and median OS were 8.8 and 17.5 months, respectively, and estimated survival at 1 year was 66%.²³⁴ Toxicities reported were similar to those seen in other trials of pomalidomide and daratumumab, except for increase in neutropenia.²³⁴

Based on the above data, the NCCN Panel has included daratumumab/pomalidomide/dexamethasone as a treatment option for patients with relapsed/refractory MM who have received at least 2 prior therapies including an IMiD and a PI and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Elotuzumab/Pomalidomide/Dexamethasone

In a phase II study, patients (n= 117) with refractory/relapsed MM and refractory to lenalidomide and a PI were randomized to receive pomalidomide/dexamethasone or pomalidomide/dexamethasone/elotuzumab.²³⁵ After a follow-up of 9.1 months, the median PFS and ORR were both more than double with elotuzumab (PFS, 10.3 months vs. 4.7; ORR, 53% vs. 26%).

The NCCN Panel has included the combination of pomalidomide/dexamethasone/elotuzumab as an option for patients who have received at least two prior therapies including an iMiD and a PI.

Ixazomib/Dexamethasone

Data from two phase I studies of single-agent ixazomib in patients with relapsed/refractory MM established the maximum tolerated dose of ixazomib to be 2.0 mg/m² on a twice-weekly schedule and 2.97 mg/m² on a weekly schedule.^{236,237} The patients in these studies had multiple prior lines of therapy (median of 4 prior lines of therapy in both studies). In the study with the weekly schedule,²³⁶ out of 30 evaluable patients the rate of PR or better (≥PR) was 27%. In the twice-weekly schedule, out of 55 evaluable patients ≥PR rate was 15%.²³⁷ Adverse events, grade ≥3, were reported in 78% (drug-related in 62%) of patients on the twice-weekly schedule²³⁷ and 65% (53%) of patients on the weekly schedule.²³⁶ These included thrombocytopenia (37%), neutropenia (17%), and skin and subcutaneous tissue disorders (8%) on the twice-weekly schedule, and thrombocytopenia (33%), neutropenia (18%), and diarrhea (17%) on the weekly schedule. Peripheral neuropathy was reported in 17% (drug-related in 12%) of patients, with no grade 3 events, on the twice-weekly schedule.²³⁷ On the weekly schedule drug-related peripheral neuropathy was reported in 20% of patients (2% grade 3).²³⁶

Subsequently, phase II trials were designed to evaluate ixazomib with or without dexamethasone in patients with myeloma who have limited prior exposure to bortezomib.^{238,239} In one trial, patients (n = 33) with relapsed MM received weekly ixazomib 5.5 mg and had dexamethasone added for suboptimal response or disease progression (in 67% of patients). Six additional patients achieved a PR after the addition of dexamethasone.²³⁸



The ORR (\geq PR) with or without the addition of dexamethasone reported was 34%.²³⁸ Adverse events, grade \geq 3, were reported in 78%. The most common adverse events observed included thrombocytopenia, fatigue, nausea, and diarrhea.²³⁸

Another phase II study evaluated two doses of weekly ixazomib (arm A, 4 mg and arm B, 5.5 mg) plus weekly dexamethasone (40 mg) in patients (n = 70) with relapsed MM. The patients enrolled in the trial had not been previously treated with a PI (including bortezomib) or had received less than 6 cycles of therapy with bortezomib and had a PR or better and no progression at the time of discontinuation.²³⁹ The ORRs were 31% in arm A (95% CI, 17–49) and 51% (95% CI, 34–69) in arm B. Among the patients with no prior bortezomib exposure the response rates were 38% for arm A and 52% for arm B.²³⁹ The most common toxicities reported in this trial were fatigue, thrombocytopenia, diarrhea, and nausea with more grade 3 toxicities among arm B. Peripheral neuropathy, possibly related to ixazomib, was seen in 55% (only grade 1 or 2) in arm A and 43% (2 patients with grade 3) in arm B.²³⁹

Based on the above phase I/II trial data, the NCCN Panel has included ixazomib/dexamethasone as a treatment option for patients with relapsed/refractory MM who have received at least one prior therapy.

Ixazomib/Pomalidomide/Dexamethasone

In phase I Alliance A061202 study (n= 22), 32% of patients were refractory to a lenalidomide/PI combination and 68% were refractory to the sequential use of these drugs. The majority of patients (65%) had high-risk cytogenetics. More than half the patients experienced grade 3 and 4 neutropenia, lymphopenia, and reductions in white blood cell count. Peripheral neuropathy, rash, diarrhea, and other side effects were limited

to grades 1 and 2. The ORR was 55% in those with PI- or lenalidomide-refractory disease and responses were found to be durable over time.²⁴⁰

Another phase I/II study studied the safety and efficacy of ixazomib/pomalidomide/dexamethasone in patients who had multiple prior therapies, were refractory to lenalidomide alone, or were refractory to lenalidomide and bortezomib, or lenalidomide, bortezomib, and carfilzomib.²⁴¹ The ORR was 33% and 40% with 2 different doses of ixazomib.²⁴¹

Considering promising preliminary response rates, especially in patients refractory to both lenalidomide and a PI, the NCCN Panel has included ixazomib/pomalidomide/dexamethasone as a treatment option for patients with relapsed/refractory MM who have received at least 2 prior therapies including an IMiD and a PI and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Elotuzumab/Bortezomib/Dexamethasone

Numerous randomized trials have shown that 3-drug combinations have been shown to be consistently more effective than 2-drug combinations for the treatment of MM. A phase II trial studied the effect of addition of elotuzumab to bortezomib/dexamethasone in patients with relapsed/refractory MM.²⁴²

Interim analysis results demonstrated a 28% reduction in risk of disease progression or death for patients in the elotuzumab-containing triple-drug arm compared to patients treated with bortezomib/dexamethasone (HR, 0.72; 70% CI, 0.59–0.88). Median PFS was significantly higher in the elotuzumab-containing arm (9.7 months vs. 6.9 months). After 2 years the addition of elotuzumab continued to show an efficacy benefit compared to



bortezomib/dexamethasone alone with a 24% relative risk reduction in PFS (HR, 0.76; 70% CI, 0.63–0.91).²⁴²

Based on the above phase II trial data, the NCCN Panel has included elotuzumab/bortezomib/dexamethasone as a treatment option for patients with relapsed/refractory MM who have received at least one prior therapy.

Panobinostat/Carfilzomib

A multicenter phase I/II study assessed the safety and efficacy of the combination of panobinostat/carfilzomib in patients with relapsed/refractory MM who had relapsed after at least one prior treatment.²⁴³ Phase I of the study was to determine the maximum tolerable dose of panobinostat and carfilzomib. The primary endpoint of the phase II was ORR.

No dose-limiting toxicities were observed at any of the planned dose levels in the phase I study. Of the 42 evaluable patients in phase II, the ORR was 67% and the clinical benefit rate was 79%.²⁴³ The ORR was 67% for patients refractory to prior PI treatment and 75% for patients refractory to prior immune-modulating drug treatment. At a median follow-up of 17 months, median PFS was 7.7 months.²⁴³ Grade 3/4 treatment-related adverse events included thrombocytopenia (38%), neutropenia (21%), fatigue (11%), anemia (9%), hypertension (9%), and diarrhea (7%).²⁴³

The maximum tolerated dose of carfilzomib and panobinostat was not reached with the 4 dosing schedules in the first phase I study;²⁴³ two additional dosing schedules were evaluated. The maximum planned dose from the first study was 30 mg panobinostat plus 20/45 mg/m² of carfilzomib. In this study,²⁴³ the dose of carfilzomib was escalated to 20/56 mg/m² in one cohort. Due to dose reductions of panobinostat in the first

study, the second cohort in this study explored 20 mg of panobinostat and carfilzomib 20/56 mg/m². The most common adverse events grade ≥3 were thrombocytopenia (31%), fatigue (4%), and diarrhea (4%). The ORR was 82% (34% ≥VGPR and 48% PR). The clinical benefit rate was 91%.

Based on promising phase I/II data, the NCCN Panel has added panobinostat in combination with carfilzomib as a treatment option for patients with previously treated MM.

Panobinostat/Bortezomib/Dexamethasone

Panobinostat is a pan-deacetylase inhibitor that epigenetically modulates class I and II HDAC enzymes.²⁴⁴ Recently, the FDA approved the use of panobinostat in combination with bortezomib and dexamethasone for patients with relapsed/refractory MM who have had at least two prior therapies with regimens containing an IMiD and bortezomib.

The approval was based on the results of a randomized, placebo-controlled, phase III study, PANORAMA-1. The study randomized 768 patients with MM who had received prior treatment with an IMiD and bortezomib to receive bortezomib and dexamethasone along with either panobinostat or placebo. The results showed an improved median PFS with the panobinostat-containing regimen compared with the control arm (11.99 months [95% CI; 10.33–12.94 months] vs. 8.08 months [95% CI; 7.56–9.23 months]; HR, 0.63; 95% CI, 0.52–0.76; *P* < .0001) along an increased depth of response.²⁴⁵ The final OS data from this study are not yet available.

The regimen containing panobinostat is associated with significant toxicity. Serious adverse events were reported in 228 (60%) of 381 patients in the panobinostat group and 157 (42%) of 377 patients in the placebo group. Common grade 3–4 laboratory abnormalities and adverse events were greater in the panobinostat group versus the control group, including



thrombocytopenia (67% vs. 31%), lymphopenia (53% vs. 40%), diarrhea (26% vs. 8%), fatigue (4% vs. 2%), and peripheral neuropathy (18% vs. 5%).²⁴⁵

The PANORAMA-2 is a phase II, single-arm, multicenter trial that evaluated the combination of panobinostat with bortezomib and dexamethasone in patients who had relapsed disease, refractory to bortezomib (N = 55).²⁴⁶ Patients in this study achieved an ORR of 34.5% with the panobinostat-containing regimen.²⁴⁶ The median PFS was 5.4 months and OS had not been reached at a median follow-up of 8.3 months.²⁴⁶ Common grade 3/4 adverse events included thrombocytopenia (63.6%), diarrhea (20.0%), and fatigue (20.0%).²⁴⁶

The NCCN Multiple Myeloma Panel has included panobinostat in combination with bortezomib and dexamethasone as a category 1 option for patients who have received at least two prior therapies, including an immunomodulator and bortezomib.

Panobinostat/Lenalidomide/Dexamethasone

A single-center, phase II study evaluated the safety and efficacy of the oral regimen containing panobinostat with lenalidomide and dexamethasone in patients (n = 27) with relapsed or relapsed/refractory MM (including those refractory to IMiD and PIs).²⁴⁷ ORR was 41% and median PFS was 7.1 months. In lenalidomide-refractory patients (n = 22), the ORR was 36% and median PFS was 6.5 months.²⁴⁷ The expected hematologic toxicities seen and GI toxicities seen with the combination of HDAC inhibitors and bortezomib was not seen in this trial.²⁴⁷

Based on the encouraging ORR and PFS in iMiD–refractory patients, the NCCN Multiple Myeloma Panel has included panobinostat with

lenalidomide and dexamethasone for patients who have received at least two prior therapies, including an immunomodulator and bortezomib.

Regimens Useful Under Certain Circumstances for Previously Treated MM

In a trial by Knop and colleagues, 31 patients who had experienced relapse after autologous transplantation were enrolled to receive increasing doses of bendamustine.²⁴⁸ The ORR was 55%, with a median PFS of 26 weeks for all patients and 36 weeks for patients who received higher doses of bendamustine (90–100 mg/m²). Toxicity was mild and mainly hematologic. A retrospective analysis of 39 patients has reported that bendamustine is effective and tolerable in patients with advanced progressive MM, with an ORR of 36%.²⁴⁹

The ECOG studied treatment with high-dose cyclophosphamide in poor-risk myeloma patients who had disease refractory to prior chemotherapy.²⁵⁰ The overall objective response rate reported was 43% (29% response rate in patients refractory to prior therapy with cyclophosphamide).²⁵⁰

Patients with an aggressive relapse may need multi-drug combinations such as DCEP,^{251–253} TD-PACE (thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide),^{254,255} and VTD-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide)^{256–258} for effective disease control.

Bendamustine is currently a treatment option for relapsed/refractory MM. High-dose cyclophosphamide is included as an option in the NCCN Guidelines for patients with relapsed/refractory MM.

The NCCN Guidelines include bendamustine, high-dose cyclophosphamide, DCEP, DT-PACE, and VTD-PACE as therapeutic



options that are useful under certain circumstances for patients with previously treated MM.

Supportive Care Treatment for Multiple Myeloma

Important advances have been made in adjunctive treatment/supportive care of patients with MM. This involves careful patient education about the probable side effects of each drug, the drug combinations being used, and the supportive care measures required. Supportive care can be categorized into those measures required for all patients and those that address specific drugs.

Bony manifestations of myeloma, in the form of diffuse osteopenia and/or osteolytic lesions, develop in 85% of patients. Related complications are the major cause of limitations in quality of life and performance status in patients with MM. A large, double-blind, randomized trial has shown that monthly use of IV pamidronate (a bisphosphonate) can decrease pain and bone-related complications, improve performance status, and, importantly, preserve quality of life in patients with Durie-Salmon stage III MM and at least one lytic lesion.^{259,260} Zoledronic acid has equivalent benefits.²⁶¹

Results from the study conducted by Zervas et al²⁶² show a 9.5-fold greater risk for the development of osteonecrosis of the jaw (ONJ) with zoledronic acid compared to pamidronate. Patients who are on bisphosphonates should have their renal function monitored. They should have a dental exam prior to start of bisphosphonate therapy and should be monitored for ONJ.

The Medical Research Council (MRC) Myeloma IX study examined effects of zoledronic acid versus clodronate (a bisphosphonate not currently FDA approved) in patients with MM initiating chemotherapy regardless of bone disease. The patients were randomized to receive zoledronic acid (n = 981) or clodronic acid (n = 979). Zoledronic acid was reported to reduce

mortality and significantly improve PFS.²⁶³ Patients on clodronate and zoledronic acid had similar occurrence of acute renal failure and treatment-related serious adverse events. Zoledronic acid was associated with higher rates of ONJ than was clodronic acid.²⁶⁴ An extended follow-up (median, 5.9 years) of the MRC Myeloma IX showed significant improvement in OS (52 vs. 46 months; HR, 0.86; $P = .01$) compared with clodronic acid.²⁶⁵ The long-term rates of ONJ were also observed to be higher with zoledronic acid compared with clodronate (3.7% vs. 0.5%; $P = .0001$).²⁶⁵

A recent meta-analysis of 20 randomized controlled trials comparing bisphosphonates with either placebo or a different bisphosphonate as a comparator concluded that adding bisphosphonates to the treatment of MM reduces vertebral fractures and probably reduces pain.²⁶⁶ It did not find a particular bisphosphonate to be superior to another.²⁶⁶

A large, placebo-controlled, randomized trial compared denosumab with zoledronic acid in patients (n = 1718) with newly diagnosed MM with bone lesions. Time to first skeletal-related events (SREs) and OS was similar in both arms. The denosumab arm had lower rates of renal toxicity and higher rates of hypocalcemia. ONJ was slightly higher in the denosumab arm (3% vs. 2%) but not statistically significant.²⁶⁷

The NCCN Guidelines for Multiple Myeloma recommend bisphosphonates (category 1) or denosumab for all patients receiving myeloma therapy for symptomatic disease regardless of documented bone disease. Denosumab is preferred by the NCCN Panel in patients with renal disease. The panel recommends a baseline dental exam and monitoring for ONJ in all patients receiving a bone-modifying agent and monitoring for renal dysfunction with use of bisphosphonate therapy.



In patients with smoldering or stage I MM, according to the NCCN Panel, bisphosphonates may be considered but preferably in a clinical trial. Skeletal survey annually or as clinically indicated is recommended for these patients. Bone densitometry or other metabolic studies should be reserved for clinical trials.

Low-dose radiation therapy (10–30 Gy) is used for the palliative treatment of uncontrolled pain, impending pathologic fracture, or impending spinal cord compression.⁴⁷ Limited involved fields should be used to limit the effect of irradiation on stem cell harvest or its effect on potential future treatments; the radiation doses administered should not preclude stem cell collection in potential candidates for high-dose therapy and hematopoietic SCT. Orthopedic consultation should be obtained for impending or actual fractures in weight-bearing bones, bony compression of the spinal cord, or vertebral column instability. Either vertebroplasty or kyphoplasty should be considered for symptomatic vertebral compression fractures.

Excess bone resorption from myeloma bone disease can lead to excessive release of calcium into the blood, contributing to hypercalcemia. Symptoms include polyuria and gastrointestinal disturbances, with progressive dehydration and decreases in glomerular filtration rate. Hypercalcemia should be treated with hydration, bisphosphonates, denosumab,²⁶⁸ steroids, and/or calcitonin. Among the bisphosphonates (zoledronic acid, pamidronate, and ibandronate), the NCCN Multiple Myeloma Panel members prefer zoledronic acid for treatment of hypercalcemia.^{261,269,270}

Plasmapheresis should be used as adjunctive therapy for symptomatic hyperviscosity.²⁷¹ Institutions differ in their use of plasmapheresis for adjunctive treatment of renal dysfunction.

Erythropoietin therapy may be considered for anemic patients, especially those with renal failure. Measuring endogenous erythropoietin levels may also be helpful in treatment planning^{272,273} (see [NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections](#)). Daratumumab can interfere with cross-matching and red blood cell antibody screening. The NCCN Panel recommends performing type and screen prior to receiving daratumumab to inform future matching.

To prevent infection: 1) IV immunoglobulin therapy should be considered for recurrent, life-threatening infections; 2) pneumococcal and influenza vaccine should also be considered; and 3) *Pneumocystis carinii* pneumonia (PCP), herpes, and antifungal prophylaxis is recommended if a high-dose regimen is used. PIs (bortezomib, carfilzomib, and ixazomib) and daratumumab treatment have been associated with an incidence of herpes zoster.^{73,74} Herpes prophylaxis is recommended in patients receiving PI or daratumumab therapy.⁷² (See [NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections](#)).

Thrombosis is relatively common when thalidomide or lenalidomide is used with steroids, and is particularly frequent when treating newly diagnosed patients. Use of prophylactic anticoagulation agents (see [NCCN Guidelines for Venous Thromboembolic Disease](#)) is recommended when IMiDs are used in combination therapy during induction.^{105,274,275}

Hydration should be maintained and nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided to decrease the chances of renal dysfunction. According to the NCCN Multiple Myeloma Panel members, the use of plasmapheresis to improve renal function is a category 2B recommendation. The use of IV contrast media should also be avoided in patients with renal impairment. Renal function should be monitored with chronic use of bisphosphonates.



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 3.2019

Multiple Myeloma

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)



References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34. Available at: <https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21551>.
2. SEER Stat Fact Sheets: Myeloma. Available at <http://seer.cancer.gov/statfacts/html/mulmy.html>.
3. Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clinical Cancer Research 2011;17:1225-1233. Available at: <http://clincancerres.aacrjournals.org/content/17/6/1225.abstract>.
4. Hideshima T, Anderson K. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-937. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12459731>.
5. U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: http://www.nlm.nih.gov/bsd/bsd_key.html.
6. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12528874>.
7. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-224. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19020545>.
8. Kuhnemund A, Liebisch P, Bauchmuller K, et al. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009;135:477-484. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18802723>.
9. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16855634>.
10. Kyle RA, Schreiman JS, McLeod RA, Beabout JW. Computed tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med 1985;145:1451-1452.
11. Pianko MJ, Terpos E, Roodman GD, et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clin Cancer Res 2014;20:5888-5897. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25294899>.
12. Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012;159:499-513. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22881361>.
13. Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235-4246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18337559>.
14. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802-809. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9680348>.
15. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-3495. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17209057>.
16. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837-2840. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15976175>.
17. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia



2007;21:143-150. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17024116>.

18. Ross FM, Chiecchio L, Dagrada G, et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. *Haematologica* 2010;95:1221-1225. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/20410185>.

19. Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. *Haematologica* 2012;97:1272-1277. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22371180>.

20. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. *Blood* 2006;108:1724-1732. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16705089>.

21. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. *Cancer Cell* 2006;9:313-325. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16616336>.

22. Rosinol L, Carrio A, Blade J, et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. *Br J Haematol* 2005;130:729-732. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16115129>.

23. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. *Mayo Clin Proc* 2007;82:323-341. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17352369>.

24. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of

Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Mayo Clin Proc 2009;84:1095-1110. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19955246>.

25. Moreau P, Attal M, Garban F, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. *Leukemia* 2007;21:2020-2024. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17625611>.

26. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. *Leukemia* 2009;23:2210-2221. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19798094>.

27. Zhou Y, Barlogie B, Shaughnessy JD, Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. *Leukemia* 2009;23:1941-1956. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19657360>.

28. Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. *J Clin Oncol* 2008;26:4798-4805. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18591550>.

29. Shaughnessy JD, Jr., Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. *Blood* 2007;109:2276-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17105813>.

30. Kuiper R, Broyl A, de Knecht Y, et al. A gene expression signature for high-risk multiple myeloma. *Leukemia* 2012;26:2406-2413. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22722715>.

31. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. *Blood* 2008;111:3941-3967.



32. Paiva B, Vidriales MB, Perez JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. *Haematologica* 2009;94:1599-1602. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19880781>

33. Mouloupoulos LA, Dimopoulos MA, Weber D, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. *J Clin Oncol* 1993;11:1311-1315. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8315427>.

34. Durie B, Waxman A, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. *J Nucl Med* 2002;43:1457-1463. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12411548>.

35. Schirrmester H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. *Eur J Nucl Med Mol Imaging* 2002;29:361-366. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12002711>.

36. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. *Blood* 2011;118:5989-5995. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21900189>.

37. Nanni C, Zamagni E, Celli M, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. *Clin Nucl Med* 2013;38:e74-79. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23143049>.

38. Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 Trial: Results of the IMAJEM study. *J Clin Oncol* 2017;35:2911-2918. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28686535>.

39. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. *Blood* 1993;81:3382-3387. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8507875>.

40. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol* 2014;15:e538-548. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25439696>.

41. Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer J* 2018;8:59. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29895887>

42. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. *J Clin Oncol* 2005;23:3412-3420. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15809451>.

43. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *J Clin Oncol* 2015;33:2863-2869. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26240224>.

44. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. *J Clin Oncol* 1983;1:255-262. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6668499>.

45. Does GM, Landgren O, McGlynn KA, et al. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. *Br J Haematol* 2009;144:86-94. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19016727>.

46. Dimopoulos MA, Goldstein J, Fuller L, et al. Curability of solitary bone plasmacytoma. *J Clin Oncol* 1992;10:587-590. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1548521>.



47. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. *Oncology (Williston Park)* 2000;14:101-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10680152>.
48. Creach KM, Foote RL, Neben-Wittich MA, Kyle RA. Radiotherapy for extramedullary plasmacytoma of the head and neck. *Int J Radiat Oncol Biol Phys* 2009;73:789-794. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18707826>.
49. Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, et al. Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. *Int J Radiat Oncol Biol Phys* 2006;64:1013-1017. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16343803>.
50. Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. *Cancer* 2011;117:4468-4474. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21437886>.
51. Frassica DA, Frassica FJ, Schray MF, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. *Int J Radiat Oncol Biol Phys* 1989;16:43-48. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2912957>.
52. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. *Int J Radiat Oncol Biol Phys* 2006;64:210-217. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16229966>.
53. Knobel D, Zouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. *BMC Cancer* 2006;6:118-118. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16677383>.
54. Sasaki R, Yasuda K, Abe E, et al. Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. *Int J Radiat Oncol Biol Phys* 2012;82:626-634. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21277117>.
55. Gerry D, Lentsch EJ. Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. *Otolaryngol Head Neck Surg* 2013;148:974-981. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23482476>.
56. Kato T, Tsukamoto E, Nishioka T, et al. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. *Clin Nucl Med* 2000;25:870-873. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11079582>.
57. Nanni C, Rubello D, Zamagni E, et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmacytoma of bone. *In Vivo* 2008;22:513-517. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18712181>.
58. Group TIMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *British Journal of Haematology* 2003;121:749-757. Available at: <http://dx.doi.org/10.1046/j.1365-2141.2003.04355.x>.
59. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *J Clin Oncol* 2002;20:1625-1634. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11896113>.
60. Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. *N Engl J Med* 2013;369:438-447. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23902483>.
61. Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smoldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. *Lancet Oncol* 2016;17:1127-1136. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27402145>.
62. Lonial S JS, Weiss M, Kumar S, et al. E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with



asymptomatic high-risk smoldering multiple myeloma (Oral Presentation: Abstract 8001). ASCO Annual Meeting 2019. Available at: <https://meetinglibrary.asco.org/record/172276/abstract>.

63. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. *Leukemia* 2009. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19421229>.

64. Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. *AJR Am J Roentgenol* 2005;184:1199-1204. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15788594>.

65. Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. *Skeletal Radiol* 2002;31:690-694. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12483429>.

66. Orchard K, Barrington S, Buscombe J, et al. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. *Br J Haematol* 2002;117:133-135. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11918544>.

67. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. *Am J Pathol* 1998;152:1655-1665. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9626070>.

68. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. *Blood* 2007;110:2586-2592. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17576818>.

69. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients With t(4;14)

myeloma but not outcome of patients with del(17p). *J Clin Oncol* 2010. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20644101>.

70. Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. *Cancer Treat Rev* 2010;36 Suppl 2:S24-32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20472185>.

71. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. *Haematologica* 2013;98:1753-1761. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23935022>.

72. Chanan-Khan A, Sonneveld P, Schuster M, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. *J Clin Oncol* 2008;26:4784-4790. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18711175>.

73. Mateos M, Hernandez J, Hernandez M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. *Blood* 2006;108:2165-2172. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16772605>.

74. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2005;352:2487-2498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15958804>.

75. FDA Safety Information. Available at: <http://www.fda.gov/safety/medwatch/safetyinformation/ucm441458.htm>.

76. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncol* 2011;12:431-440. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21507715>.

77. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. *Haematologica*



2012;97:1925-1928. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22689676>.

78. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood* 2010;116:679-686. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20385792>.

79. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. *Blood* 2012;119:4375-4382. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22422823>.

80. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. *J Clin Oncol* 2014;32:2712-2717. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25024076>.

81. Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet* 2017;389:519-527. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28017406>.

82. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. *Leukemia* 2009;23:1337-1341. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19225538>.

83. Knop S, Liebisch P, Wandt H, et al. Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM

Xia trial. 2009;27:8516-8516. Available at:

<https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15s.8516>.

84. Reeder CB, Reece DE, Kukreti V, et al. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. *Br J Haematol* 2014;167:563-565. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24974945>.

85. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. *Blood* 2010;115:3416-3417. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20413666>.

86. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. *J Clin Oncol* 2012;30:2946-2955. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22802322>.

87. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood* 2012;120:2817-2825. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22833546>.

88. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. *Blood* 2012;119:5661-5670. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22555973>.

89. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. *Blood* 2012;120:1801-1809. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22665938>.

90. Korde N, Zingone A, Kwok M, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly



diagnosed Multiple Myeloma (MM) patients [abstract]. Blood 2012;120:Abstract 732. Available at: <http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/732>.

91. Korde N, Zingone A, Kwok M, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients [Abstract]. Blood 2013 Vol. 122; 538-538.

92. Zimmerman T, Raje NS, Vij R, et al. Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). Presented at: the 58th American Society of Hematology Annual Meeting and Exposition; 2016; San Diego, CA. (suppl:abstract 1142).

93. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014;15:1503-1512. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25456369>.

94. Dytfeld D, Jasielec J, Griffith KA, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica 2014;99:e162-164. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24972772>.

95. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-4629. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20823406>.

96. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma

Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9753033>.

97. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12826635>.

98. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752-5758; quiz 5982. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21849487>.

99. Kumar SK, Lacy MQ, Hayman SR, et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011;86:640-645. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21630308>.

100. Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): Results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232 [abstract]. Blood 2007;110:Abstract 77. Available at: <http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/77>.

101. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2007;110:Abstract 74. Available at: <http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/74>.

102. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).



Blood 2010;116:5838-5841. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20876454>.

103. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. *Lancet Oncol* 2010;11:29-37. Available at: <http://www.ncbi.nlm.nih.gov/sites/entrez/19853510>

104. Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. *J Clin Oncol* 2010;28:132-135. Available at: <http://www.ncbi.nlm.nih.gov/sites/pubmed/19901114>.

105. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. *Leukemia* 2008;22:414-423. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18094721>.

106. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia* 2007;21:2035-2042. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17581613>.

107. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. *Leukemia* 2008;22:1282-1284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18216870>.

108. Kumar S, Giral S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. *Blood* 2009;114:1729-1735. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19561323>.

109. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. *Biol Blood Marrow*

Transplant 2008;14:795-798. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/18541199>.

110. Nademanee AP, DiPersio JF, Maziarz RT, et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. *Biol Blood Marrow Transplant* 2012;18:1564-1572. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22683613>.

111. Duarte RF, Shaw BE, Marin P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. *Bone Marrow Transplant* 2010. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20305700>.

112. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet* 2010;376:2075-2085. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21146205>.

113. Kaufman JL, Nooka A, Vrana M, et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. *Cancer* 2010;116:3143-3151. Available at: <http://www.ncbi.nlm.nih.gov/sites/pubmed/20564642>.

114. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. *Blood* 2012;120:1589-1596. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22791289>.

115. Moreau P, Hulin C, MACRO M, et al. Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the prospective IFM



2013-04 trial. Blood 2015;126:393-393. Available at:
<http://www.bloodjournal.org/content/126/23/393>.

116. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176-185. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/17593024>.

117. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. New England Journal of Medicine 2014;371:906-917. Available at:
<http://www.nejm.org/doi/full/10.1056/NEJMoa1402551>.

118. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782-1791. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/22571202>.

119. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-1781. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/22571201>.

120. Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012;120:1597-1600. Available at:
<http://bloodjournal.hematologylibrary.org/content/120/8/1597.abstract>.

121. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014;15:333-342. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24525202>.

122. Dimopoulos MA, Cheung MC, Roussel M, et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica 2016;101:363-370. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26659916>.

123. Hulin C, Belch A, Shustik C, et al. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. J Clin Oncol 2016;34:3609-3617. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/27325857>.

124. Zepeda J, H. V, Duggan P, et al. Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant eligible multiple myeloma patients [Abstract]. Blood 2014;124:5751-5751. Available at:
<http://www.bloodjournal.org/content/124/21/5751>.

125. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 2018;378:518-528. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/29231133>.

126. Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26181891>.

127. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014;124:63-69. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24855212>.

128. Niesvizky R, Flinn IW, Rifkin R, et al. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. J Clin Oncol 2015;33:3921-3929. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26056177>.

129. Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: Results from all randomized patients in the community-based, phase 3b UPFRONT study [abstract]. Blood 2011;118:Abstract 478. Available at:
<http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/478>.



130. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. *Am J Hematol* 2011;86:57-65. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21181954>.

131. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *J Clin Oncol* 2014;32:587-600. Available at: <http://jco.ascopubs.org/content/32/6/587.long>.

132. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol* 2016;17:e328-346. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27511158>.

133. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. *Blood* 2001;97:2574-2579. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11313244>.

134. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. *Blood* 2002;100:3919-3924. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12393448>.

135. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m² melphalan and 8 Gy total body irradiation plus 140 mg/m² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. *Blood* 2002;99:731-735. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11806971>.

136. Somlo G, Spielberger R, Frankel P, et al. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. *Clin Cancer Res*

2011;17:174-182. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21047977>.

137. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. *N Engl J Med* 1996;335:91-97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8649495>.

138. Child J, Morgan G, Davies F, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. *N Engl J Med* 2003;348:1875-1883. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12736280>.

139. Barlogie B, Kyle R, Anderson K, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. *J Clin Oncol* 2006;24:929-936. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16432076>.

140. Fermand J, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. *J Clin Oncol* 2005;23:9227-9233. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16275936>.

141. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. *Blood* 1998;92:3131-3136. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9787148>.

142. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. *N Engl J Med* 2014;371:895-905. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25184862>.

143. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell



transplantation in patients with newly diagnosed multiple myeloma. Blood 2012. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22498745>.

144. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017;376:1311-1320. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28379796>.

145. Attal M, Harousseau J, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14695409>.

146. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-2441. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17485707>.

147. Sonneveld P, van der Holt B, Segeren C, et al. Intensive versus double intensive therapy in untreated multiple myeloma: Updated analysis of the randomized phase III study HOVON 24 MM [abstract]. Blood 2004;104:Abstract 948. Available at: <http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/948>.

148. Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol 2016;173:731-741. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26990892>.

149. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010;28:1209-1214. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20085933>.

150. Stadtmauer A, Pasquini M, Blackwell B, et al. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib,

lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem auto-HCT with Len maintenance (TAM) and AutoHCT with Len maintenance (AM) for up-front treatment of patients with Multiple Myeloma (MM): Primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial). ASH annual meeting 2016 ; Late breaking Abstract. Available at: <https://ash.confex.com/ash/2016/webprogram/Paper98809.html>.

151. Petrucci T, Raimondo FD, Zamagni E, et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: An intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial (Oral Presentation). 2016 ASH annual meeting. Available at: <https://ash.confex.com/ash/2016/webprogram/Paper93518.html>.

152. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol 2019;37:589-597. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30653422>.

153. Cook G, Liakopoulou E, Pearce R, et al. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21565277>.

154. Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417-422. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18850013>.

155. Burzynski JA, Toro JJ, Patel RC, et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009;50:1442-1447. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19637091>.

156. Alvares CL, Davies FE, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica



2006;91:141-142. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16434386>.

157. Fenk R, Liese V, Neubauer F, et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. *Leuk Lymphoma* 2011;52:1455-1462. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21657961>.

158. Cook G, Williams C, Brown JM, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014;15:874-885. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24948586>.

159. Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. *The Lancet Haematology*;3:e340-e351. Available at: [http://dx.doi.org/10.1016/S2352-3026\(16\)30049-7](http://dx.doi.org/10.1016/S2352-3026(16)30049-7).

160. Auner HW, Szydlo R, Rone A, et al. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. *Leuk Lymphoma* 2013;54:2200-2204. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23387937>.

161. Jimenez-Zepeda VH, Mikhael J, Winter A, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: Impact on progression-free and overall survival. *Biol Blood Marrow Transplant* 2012;18:773-779. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22062804>.

162. Sellner L, Heiss C, Benner A, et al. Autologous retransplantation for patients with recurrent multiple myeloma: A single-center experience with 200 patients. *Cancer* 2013;119:2438-2446. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23576287>.

163. Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. *Cancer* 2012;118:3549-3555. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22086552>.

164. Kyle RA. High-dose therapy in multiple myeloma and primary amyloidosis: an overview. *Semin Oncol* 1999;26:74-83. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10073564>.

165. Kumar A, Loughran T, Alsina M, et al. Management of multiple myeloma: a systematic review and critical appraisal of published studies. *Lancet Oncol* 2003;4:293-304. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12732167>.

166. Hahn T, Wingard J, Anderson K, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. *Biol Blood Marrow Transplant* 2003;9:4-37. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12533739>.

167. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. *N Engl J Med* 2007;356:1110-1120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17360989>.

168. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. *Blood* 2008;112:3591-3593. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18612103>.

169. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. *Blood* 2006;107:3474-3480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16397129>.

170. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. *Lancet Oncol*



2011;12:1195-1203. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21962393>.

171. Bjorkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. *J Clin Oncol* 2011;29:3016-3022. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21730266>.

172. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. *Blood* 2001;97:2574-2579. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11313244>.

173. Maloney D, Molina A, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. *Blood* 2003;102:3447-3454. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12855572>.

174. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. *Blood* 2005;105:4532-4539. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15731182>.

175. de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. *Bone Marrow Transplant* 2008;41:953-960. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18297115>.

176. Putkonen M, Kairisto V, Juvonen V, et al. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. *Eur J Haematol* 2010;85:416-423. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20722702>.

177. Zeiser R, Bertz H, Spyridonidis A, et al. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. *Bone Marrow*

Transplant 2004;34:923-928. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15361911>.

178. van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. *Bone Marrow Transplant* 2006;37:1135-1141. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16757975>.

179. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. *Blood* 2004;103:4362-4364. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/14976044>.

180. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. *J Clin Oncol* 2000;18:3031-3037. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10944138>.

181. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. *Blood* 1997;90:4206-4211. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9354693>.

182. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. *Bone Marrow Transplant* 2000;26:1179-1184. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11149728>.

183. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-multiple myeloma effect: proof of principle. *Blood* 1996;87:1196-1198. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8562947>.

184. Ayuk F, Shimoni A, Nagler A, et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. *Leukemia* 2004;18:659-662. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/14671630>.



185. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. *Blood* 2008;112:4017-4023. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18669875>.

186. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. *J Clin Oncol* 2013;31:2540-2547. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23733781>.

187. Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. *Lancet Haematol* 2017;4:e431-e442. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28826616>.

188. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. *J Clin Oncol* 2017;35:3279-3289. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28742454>.

189. Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. *Blood* 2011;118:2413-2419. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21690556>.

190. Alsina M, Becker PS, Zhong X, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 2014;20:1183-1189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24769014>.

191. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med*

2012;366:1759-1769. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22571200>.

192. Singh P, Kumar SK, LaPlant BR, et al. Lenalidomide Maintenance Therapy in multiple myeloma: A meta-analysis of randomized trials. 2013;122:407-407. Available at: <http://www.bloodjournal.org/content/122/21/407?sso-checked=true>.

193. Kumar SK, LaPlant BR, Gertz MA, et al. Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. 2013;122:407-407. Available at: <http://www.bloodjournal.org/content/122/21/407?sso-checked=true>.

194. Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. *Ann Oncol* 2017;28:228-245. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27864218>.

195. Mellqvist UH, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. *Blood* 2013;121:4647-4654. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23616624>.

196. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. *J Clin Oncol* 2009;27:5713-5719. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19786667>.

197. Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. *Blood* 2014;123:1461-1469. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24429336>.

198. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2015;372:142-152. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25482145>.



199. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol* 2016;17:27-38. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26671818>.

200. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. *Lancet Oncol* 2017;18:1327-1337. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28843768>.

201. Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. *Blood* 2016;127:3360-3368. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27207788>.

202. Berdeja JG, Rifkin RM, Lyons R, et al. Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure. *Blood* 2016;128:2129-2129. Available at: <http://www.bloodjournal.org/content/128/22/2129?sso-checked=true>.

203. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016;375:754-766. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27557302>.

204. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. *N Engl J Med* 2015;373:1207-1219. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26308596>.

205. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet* 2016;387:1551-1560. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26778538>.

206. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016;375:1319-1331. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27705267>.

207. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. *Clin Cancer Res* 2008;14:2775-2784. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18451245>.

208. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med* 2015;373:621-631. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26035255>.

209. Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. *Br J Haematol* 2017;178:896-905.

210. Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016;374:1621-1634. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27119237>.

211. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. *Blood* 2012;119:4608-4613. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22451423>.

212. Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. *Blood Cancer J* 2013;3:e162. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24270324>.

213. Orlowski R, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. *J Clin Oncol* 2007;25:3892-3901. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17679727>.



214. Davies FE, Wu P, Jenner M, et al. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. *Haematologica* 2007;92:1149-1150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17650451>.

215. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. *Br J Haematol* 2007;138:330-337. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17614819>.

216. Mikhael JR, Belch AR, Prince HM, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. *Br J Haematol* 2009;144:169-175. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19036114>.

217. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. *Br J Haematol* 2004;127:165-172. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15461622>.

218. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. *Haematologica* 2006;91:929-934. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16818280>.

219. Yong K, Brown S, Hinsley S, et al. Carfilzomib, cyclophosphamide and dexamethasone is well tolerated in patients with relapsed/refractory multiple myeloma who have received one prior regimen. 2015;126:1840. Available at: <https://ash.confex.com/ash/2015/webprogramscheduler/Paper82080.html>.

220. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. *N Engl J Med* 2007;357:2123-2132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18032762>.

221. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. *N Engl J Med* 2007;357:2133-2142. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18032763>.

222. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. *Blood* 2009;114:772-778. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19471019>.

223. Morgan GJ, Schey SA, Wu P, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. *Br J Haematol* 2007;137:268-269. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17408469>.

224. Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. *Blood* 2010;116:3227-3237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20651070>.

225. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2013;14:1055-1066. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24007748>.

226. Dimopoulos MA, Palumbo A, Weisel K, et al. Safety and efficacy in the stratus (MM-010) trial, a single-arm phase 3b study evaluating pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. Vol. 124; 2014:80-80. Available at: <http://www.bloodjournal.org/content/124/21/80>.

227. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. *Blood* 2013;121:1968-1975. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23319574>.



228. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood* 2011;118:2970-2975. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21690557>.

229. Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2019. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31097405>.

230. Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. *Blood* 2015;126:2284-2290. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26384354>.

231. Rosenbaum CA, Stephens LA, Kukreti V, et al. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study. *ASCO Meeting Abstracts* 2016;34:8007. Available at: http://meeting.ascopubs.org/cgi/content/abstract/34/15_suppl/8007.

232. Baz RC, Martin TG, 3rd, Lin HY, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. *Blood* 2016;127:2561-2568. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26932802>.

233. Garderet L, Guelongo OOJ, Beohou E, et al. Pomalidomide, Cyclophosphamide and Dexamethasone for relapsed/refractory multiple myeloma: a retrospective single center experience [Poster]. Poster presented at: 57th Annual Meeting and Exposition of the American Society of Hematology (ASH); December 5-8, 2015; Orlando, FL, USA. Available at: <https://ash.confex.com/ash/2015/webprogramscheduler/Paper85037.html>.

234. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple

myeloma. *Blood* 2017;130:974-981. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28637662>.

235. Dimopoulos MA, Dytfield D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. *N Engl J Med* 2018;379:1811-1822. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30403938>.

236. Kumar SK, Bensinger WL, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. *Blood* 2014;124:1047-1055. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24904120>.

237. Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. *Blood* 2014;124:1038-1046. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24920586>.

238. Kumar SK, LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. *Blood Cancer J* 2015;5:e338. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26275080>.

239. Kumar SK, Laplant BR, Reeder CB, et al. Randomized phase 2 trial of two different doses of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. *Blood* 2015;126:3050-3050. Available at: <http://www.bloodjournal.org/content/126/23/3050>.

240. Voorhees PM, Mulkey F, Hassoun H, et al: Alliance A061202, a phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results. 2015 ASH Annual Meeting. Abstract 375. Presented December 6, 2015. Available at: <https://ash.confex.com/ash/2015/webprogramscheduler/Paper82080.html>.

241. Krishnan AY, Kapoor P, Palmer J, et al. A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results. *Journal of Clinical*



Oncology 2016;34:8008-8008. Available at:
http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.8008.

242. Jakubowiak A, Offidani M, Pegourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood 2016;127:2833-2840. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/27091875>.

243. Berdeja JG, Hart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica 2015;100:670-676. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25710456>.

244. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009;280:233-241. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19344997>.

245. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15:1195-1206. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/25242045>.

246. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013;122:2331-2337. Available at:
<http://bloodjournal.hematologylibrary.org/content/122/14/2331.abstract>.

247. Chari A, Cho HJ, Dhadwal A, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Advances 2017;1:1575-1583. Available at:

248. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-1288. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16154860>.

249. Michael M, Bruns I, Bolke E, et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15:13-19. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20159666>.

250. Lenhard RE, Jr., Oken MM, Barnes JM, et al. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 1984;53:1456-1460. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/6697291>.

251. Lazzarino M, Corso A, Barbarano L, et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001;28:835-839. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/11781643>.

252. Dadacaridou M, Papanicolaou X, Maltesas D, et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON 2007;12:41-44. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17436400>.

253. Griffin PT, Ho VQ, Fulp W, et al. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer 2015;121:3622-3630. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/26149422>.

254. Lee C, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-2739. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/12860952>.

255. Srikanth M, Davies FE, Wu P, et al. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 2008;81:432-436. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/18691254>.

256. Buda G, Orciuolo E, Galimberti S, et al. VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients. Blood 2013;122:5377-5377.



257. Andoh S, Togano T, Itoi S, et al. Efficacy and Safety of VTD-PACE Regimen in Relapsed or Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*;17:e57. Available at: <http://dx.doi.org/10.1016/j.clml.2017.03.104>.

258. Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *Am J Hematol* 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29067723>.

259. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. *J Clin Oncol* 1998;16:593-602. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9469347>.

260. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. *N Engl J Med* 1996;334:488-493. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8559201>.

261. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. *J Clin Oncol* 2001;19:558-567. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11208851>.

262. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. *Br J Haematol* 2006;134:620-623. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16889620>.

263. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. *Lancet* 2010;376:1989-1999. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21131037>.

264. Jackson GH, Morgan GJ, Davies FE, et al. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma:

Medical Research Council Myeloma IX Study results. *Br J Haematol* 2014;166:109-117. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24673708>.

265. Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. *Clin Cancer Res* 2013;19:6030-6038. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23995858>.

266. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. *Cochrane Database Syst Rev* 2012;5:CD003188. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22592688>.

267. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. *Lancet Oncol* 2018;19:370-381. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29429912>.

268. Raje N, Terpos E, Willenbacher W, et al. An International, Randomized, Double Blind Trial Comparing Denosumab with Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) with Newly Diagnosed Multiple Myeloma. Presented at: 16th International Myeloma Workshop (IMW); March 4, 2017; New Delhi, India.

269. Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. *Semin Oncol* 2001;28:17-24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11346861>.

270. Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. *Support Care Cancer* 2003;11:539-547. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12783289>.

271. Lindsley H, Teller D, Noonan B, et al. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of



the myeloma protein. Am J Med 1973;54:682-688. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/4701949>.

272. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2342535>.

273. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996;87:2675-2682. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8639883>.

274. Ikhlake N, Seshadri V, Kathula S, Baumann M. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006;81:420-422. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16680743>.

275. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005;80:1568-1574. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16342649>.